| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Tumor Immunology, University Medical Center Nijmegen, Nijmegen, The Netherlands (F.A.D.T.G.W., G.J.A., C.G.F.); Department of Medical Immunology, Charité, Humboldt University, Berlin, Germany (H.-D.V.); Department of Pharmacology, University College, London, England (D.W.); Department of Pharmacology, New York Medical College, Valhalla, New York (N.G.A.); Beth Israel Deaconess Medical Center, Department of Surgery, Harvard Medical School, Boston, Massachusetts (M.P.S.); and Inflammation Laboratory, Institute Gulbenkian for Science, Lisbon, Portugal (M.P.S.)
 |
Abstract |
|---|
 Top Next |
|---|
|
I. Introduction |
|---|
|
TopPreviousNext |
|---|
, 1988; Beri and Chandra, 1993; Sassa and Nagai, 1996; Ponka, 1999). It is therefore of fundamental importance for life and has fascinated many investigators for decades.
Heme oxygenase (HO2), the heme-degrading enzyme, however, obtained only scarce attention after its discovery in 1968 (Tenhunen et al., 1968), but during the last 10 years, this enzyme has rapidly gained interest from a fast growing group of scientists. The potential properties of the heme-heme oxygenase system and the multiple and diverse functions of its downstream effector molecules are mesmerizing (Lane, 1998; Maines, 2000). Recently, an overwhelming body of evidence indicates that the heme-heme oxygenase system is tightly involved in the regulation of many physiological as well as pathophysiological processes, such as cytoprotection, apoptosis, and inflammation (Maines, 1997).
Unfortunately, in some instances inflammatory and immune reactions are induced against the "wrong targets" (e.g., self-antigens in the case of autoimmune diseases), or the resolution of inflammation does not occur, resulting in severe and even irreversible tissue injury (Moore, 1999). Vascular diseases such as atherosclerosis, vasculitis, graft failure, ischemia/reperfusion injury, rheumatism, restenosis, and autoimmune diseases are all associated with oxidative stress- and inflammation-induced injury (Brod, 2000). It is therefore of utmost importance to better understand the onset and resolution of inflammation in order to develop new therapies.
In this review, a historic overview, the biosynthesis and the significance of heme and heme oxygenase is presented in view of biological and pathological processes, with special reference to inflammation. In addition, the heme-HO system is discussed in relation to apoptosis and transplantation biology.
|
II. Heme |
|---|
|
TopPreviousNext |
|---|
). Its structure is depicted in Fig. 1A.
|
The structure of heme (Fig. 1A) was confirmed after complete organic synthesis by Hans Fischer (1881-1945) and coworkers in 1927 (Watson, 1965). In 1944, David Shemin set out experiments to determine the half-life of hemoglobin (Fig. 1B) and other blood proteins. He ingested 66 g of the simplest amino acid, glycine, containing the stable isotope 15N (nitrogen), to follow its incorporation into his own blood components. As he expected, a continuous synthesis and degradation of proteins in the blood plasma was found, and the half-life was estimated to be less than 5 days. However, to his surprise, the constituents in the red blood cells, once formed, had an average life span of 127 days and would only then be destroyed (Shemin and Rittenberg, 1946; Shemin, 1989). Indeed, when red blood cells mature both heme and hemoglobin synthesis ceases. They must therefore survive for the life of the erythrocyte (approximately 120 days). Thus, hemoglobin, in contrast to all other proteins previously examined by these techniques, is not in a dynamic state.
Interestingly, thorough analysis of these data demonstrated that glycine has to be the nitrogenous precursor of heme, the functional nonprotein component of hemoglobin (Shemin and Wittenberg, 1951; Shemin, 1970; Shemin, 1989). Additional experiments in laboratory animals confirmed the novel insight that glycine was incorporated into heme. This first observation eventually led to the unraveling of the heme molecule from glycine and another body component, succinyl coenzyme A. Shemin and colleagues subsequently unraveled the complete set of enzymes involved in the synthesis of heme from these small precursors (Fig. 2) (Shemin and Wittenberg, 1951; Shemin et al., 1953; Shemin, 1970, 1989; Kappas et al., 1995b).
|
Heme is synthesized in all human nucleated cells. It involves a series of enzymatic reactions taking place partly in the mitochondrion and partly in the cytoplasm (Fig. 2). Heme requirements vary significantly among various cells and tissues. The most rapid rates of heme synthesis occur in the erythroid cells in the bone marrow [75% of total body heme (Berk et al., 1976)] and the hepatocytes in the liver, because of the incorporation of heme into the heme proteins, hemoglobin and cytochrome P450 synthesized in very high quantities in these respective organs. Probably, most mammalian cells contain a "free" or "uncommitted" heme pool, serving both precursor and regulatory functions (Fig. 2) (Ponka, 1999).
Senescent red blood cells are removed from the circulation and degraded by the reticuloendothelial system (RES) in the spleen, liver, and bone marrow (Abraham et al., 1988). As such, heme turnover is high for erythropoiesis (
250 mg/day) and cytochrome synthesis (50 mg/day). Heme derived from denatured heme proteins other than hemoglobin is probably degraded locally by HO.
As a consequence of its vital importance in biological processes, a partial defect in one of the enzymes used in heme biosynthesis is associated with a number of disease states. Examples of these inherited or acquired disorders are porphyrias, myelodysplastic syndrome, and sideroblastic anemia (Bottomley and Muller-Eberhard, 1988; Volin et al., 1988).
B. Heme As Active Site in Heme Proteins
The heme molecule provides a multitude of crucial biological functions. It can interact with various inactive apo-heme proteins giving rise to functional heme proteins. The function of the heme molecule is ultimately determined by the properties of the polypeptide bound to it (Dawson, 1988). In hemoglobin (Fig. 1B) and myoglobin, it is used for oxygen transport and storage, respectively, whereas in cytochromes it is involved in electron transport, energy generation, and chemical transformation. In catalases and peroxidases, heme functions in H2O2 inactivation or activation, respectively, and in tryptophan pyrrolase, it catalyzes the oxidation of tryptophan (Maines, 1997). Furthermore, heme is indispensable for a wide array of other important enzyme systems, such as cyclooxygenase (COX) and nitric-oxide synthase (NOS) (Seed and Willoughby, 1997).
C. Heme-Mediated Gene Modulation, Cell Differentiation, Proliferation, and Immune Stimulation
Besides its function as prosthetic moiety in heme proteins, heme itself may influence the expression of many genes. In nonerythroid cells, heme regulates its own production by down-regulating heme biosynthesis (at the level of the rate-limiting enzyme 5-aminolevulinic acid synthase (see Fig. 2) and by up-regulating heme metabolism (Yamamoto et al., 1982). In contrast, in erythroid cells, heme serves as a positive feedback regulator for heme synthesis (at the level of ferrochelatase [see Fig. 2)] and inhibits its degradation (Sassa, 1976; Rutherford and Harrison, 1979).
Heme may affect a wide spectrum of regulatory factors and can influence gene expression at almost every level by regulating transcription (Pfeifer et al., 1989; Lathrop and Timko, 1993; Zhang and Guarente, 1995), mRNA stability (Maniatis et al., 1976), protein synthesis via eIF-2
kinase (Chen et al., 1994), splicing (Ponka, 1999; Zhu et al., 1999), and post-translational modification (Swenson et al., 1991). Furthermore, heme is important in controlling the expression of numerous proteins, such as globin, heme biosynthetic enzymes, cytochromes, myeloperoxidase, heme oxygenase-1, and the transferrin receptor (Gidari and Levere, 1977). A number of these genes are regulated via heme response elements (HREs).
Using differential display, Zhu and coworkers showed that heme also strongly induces genes other than those encoding heme proteins (Sassa and Nagai, 1996; Zhu et al., 1999). These include growth-associated protein p-62 (involved in Ras signaling), chaperonin Tcp20, histone H2A.Z, and a subunit of the small nuclear ribonucleo-protein complex (involved in splicing) (Zhu et al., 1999). On the other hand, heme represses other genes, such as the H+-ATPase proton channel subunit and a cellular immediate-early response gene (Zhu et al., 1999).
It has long been hypothesized that a heme protein is involved in oxygen sensing, which is important in various molecular and cellular processes. However, in mammalians no such protein has been found yet. In yeast, heme signals are mainly mediated by the heme activator protein Hap1, which in response to heme, activates the transcription of genes necessary for respiration and control of oxidative damage (Pfeifer et al., 1987; Lee et al., 2001). Heme repression is achieved through the action of the ROX1 repressor, the expression of which is transcriptionally activated by heme (Zhang and Hach, 1999).
Recently, a mammalian transcription repressor, Bach1, was identified, which is inactivated upon heme binding (Ogawa et al., 2001). Bach1 competes with activators, including Nrf2, for the binding to Maf recognition element (MARE). HREs share a nucleotide sequence with the MARE, which is important in development and differentiation (Motohashi et al., 1997; Ogawa et al., 2001). Therefore, stress response genes bearing MARE may be up-regulated via the MARE-binding transcription factors with increased levels of heme (Ogawa et al., 2001).
In addition, heme regulates differentiation and proliferation of various cell types. It stimulates neuronal differentiation of mouse neuroblastoma cells (Ishii and Maniatis, 1978), erythroid differentiation of erythro-leukemia cells of mouse (Granick and Sassa, 1978) and man (Benz et al., 1980), formation of erythroid colonies in mouse as well as in human bone marrow cultures (Partanen et al., 1988; Abraham, 1991), differentiation of 3T3 fibroblasts into adipocytes (Chen and London, 1981), and it stimulates cell growth of cultured fibroblasts (Verger et al., 1983). Moreover, heme possesses also stimulating activity on anti-tumor immune responses (Tsuji et al., 1993).
D. Toxic Effects of Free Heme and Its Control
In contrast to the many positive functions of heme, there is accumulating evidence that an excess of free heme can cause cell damage and tissue injury since heme catalyzes the formation of reactive oxygen species (ROS), resulting in oxidative stress (Vercellotti et al., 1994; Jeney et al., 2002) (Fig. 2). Because the low-molecular weight iron chelate, heme, is lipophilic it can easily intercalate in the membrane and impair lipid bilayers and organelles, such as mitochondria and nuclei, and destabilize the cytoskeleton (Balla et al., 1991; Beri and Chandra, 1993; Ryter and Tyrrell, 2000).
Various autoimmune infectious (such as malaria) and inherited (e.g., sickle cell disease) disorders are complicated by myolysis or hemolysis, and tissues can subsequently be exposed to large amounts of free heme/heme proteins (Fig. 3) (Zager, 1996). The cellular "free heme pool" may increase after extracellular heme overload, increased heme synthesis, accelerated breakdown of heme proteins, impaired incorporation into apo-heme proteins, or because of diminished HO activity, resulting in increased levels of ROS and, subsequently, oxidative damage and cellular injury (Maines, 1992; Ryter and Tyrrell, 2000).
|
Several defense mechanisms against free heme-mediated oxidative stress and inflammation exist in mammals. They consist of intra- (e.g., heme-binding protein 23, HO-2, and HO-3) and extracellular (e.g., hemopexin, albumin) scavengers, anti-oxidative enzymes, and HO-1(Muller-Eberhard and Fraig, 1993; Immenschuh et al., 1997; Maines, 1997; Castellani et al., 2000). During hemolysis, free vascular hemoglobin is captured by its scavenger haptoglobin and transported to the RES. However, hemoglobin can be rapidly converted into methemoglobin, which liberates the incorporated heme group easily. Any free vascular heme is bound to the plasma proteins hemopexin or albumin, which transport it to the liver for degradation in the RES (Muller-Eberhard and Fraig, 1993). However, when large amounts of free heme proteins or heme (locally) accumulate, like in a blood clot or after vascular deposition, the scavengers get overwhelmed or are unable to reach them (Muller-Eberhard et al., 1968; Jacob, 1994; Wagener et al., 2001b; Jeney et al., 2002). This enables heme to exert its damaging effects.
In summary, heme exerts a dual role: in small amounts it acts by itself or as the functional group of heme proteins providing diverse and indispensable cellular functions, whereas in excessive amounts, free heme can cause severe tissue damage (Balla et al., 2000; Ryter and Tyrrell, 2000; Jeney et al., 2002). Therefore, the amount of free heme must be tightly controlled to maintain cellular homeostasis and avoid pathological conditions.
|
III. Heme Oxygenase: The Heme-Degrading Enzyme |
|---|
|
TopPreviousNext |
|---|
; Maines, 1997; Montellano, 2000) (Fig. 4).
|
The first who presumed a link between red blood cell breakdown and biliverdin was probably Virchow (1847). The connection between heme and bilirubin was made by Kuster, who noted in the beginning of the 20th century that the structures were "closely related".
Early experiments of Shemin's group demonstrated that after administration of 15N-labeled glycine, at least 20% of the heme was metabolized into 15N-labeled bile pigments as observed in the feces of volunteers within the 1st week after administration (London et al., 1950; Shemin, 1989). Furthermore, administration of labeled heme into rats showed conversion into bilirubin in the liver (Ostrow et al., 1962). In 1964, Wise and colleagues confirmed this conversion in an in vitro cell-free system (Wise and Drabkin, 1964).
In 1968, Tenhunen and coworkers presented the first evidence that in the conversion of heme to biliverdin/bilirubin, the enzyme HO is involved (Tenhunen et al., 1968). They purified HO from the microsomal fraction of the liver and spleen (Tenhunen et al., 1969). They found that HO activity had an absolute stoichiometric requirement for NADPH and molecular O2 and generated equimolar amounts of bilirubin and CO.
Tenhunen et al. (1969) reported that the microsomal HO system was not only active in heme degradation but also in the biotransformation of xenobiotics (Tenhunen et al., 1969). Thus, it was assumed that the multiple-functioned microsomal HO system was a heme protein functioning both as cytochrome P450 enzyme and terminal oxidase. However, they also demonstrated that known cytochrome P450 substrates, such as hexobarbital, aminopyrine, and cytochrome P450 inhibitors, failed to inhibit HO activity.
Maines and Kappas (1974, 1975) investigated this apparent discrepancy further, using the heavy metal cobalt, which is known to decrease both hepatic microsomal drug metabolism and the microsomal content of cytochrome P450 (Tephly et al., 1971). Rats that were fed with cobalt chloride, indeed showed a major decrease in cytochrome P450 content in microsomes of the liver, whereas, in striking contrast, the HO system increased its activity up to 8-fold. In addition, drug oxidation in microsomes was eliminated after treatment with urea, whereas HO activity levels did not change despite the absence of spectrally detectable cytochrome P450. Herewith was shown for the first time that the protein components of heme catabolism and drug metabolism were distinct and that cytochrome P450 was not required for heme oxidation.
Similarly, Yoshida and Kikuchi (1974) demonstrated that there was a high specific HO activity present in the spleen, in contrast to cytochrome P450 activity. Furthermore, they observed the absence of cytochrome P450 in their preparation of spleen microsomes but, in addition, reported the requirement of NADPH-cytochrome c (P450) reductase for enzymatic activity. Thus, the heme-degrading activity was solely attributable to HO. In addition, oxygen and hydrogen, donated by e.g., NADPH-cytochrome c (P450) reductase or NOS, are needed for the reaction (Fig. 4A).
B. Heme Oxygenase Isoforms and Gene Regulation
To date, three isoforms of heme oxygenase have been identified (HO-1, HO-2, and HO-3) (Maines, 1997). These are products of different genes, and their expression differs greatly between cell types, tissue distribution, and regulation (Table 1) (Maines, 1997; Otterbein and Choi, 2000; Maines and Panahian, 2001). They have a molecular weight of approximately 32, 36, and 33 kDa, respectively. The HO proteins are anchored to the endoplasmic reticulum by a hydrophobic sequence of amino acids at the carboxyl terminus of the protein.
|
Maines et al. (1986) were the first to report the identification of a second form of HO from rat liver microsomes, designated HO-2. Only recently, a third isoform, HO-3, was discovered (McCoubrey et al., 1997). HO-1 and HO-2 share little similarity in amino acid sequence (40%), whereas the HO-2 and HO-3 isoform are far more homologous (90%). All HO isoforms are highly conserved among species in evolution. HO is expressed in virtually all life forms; in prokaryotic bacteria as well as in fungi, plants, and humans, regulating a wide spectrum of cellular processes (Terry et al., 2002). The homology between rat, mouse, and human is for HO-1 and HO-2 proteins higher than 80% and 90%, respectively.
Under normal physiological conditions, most cells express low or undetectable levels of HO-1 protein, whereas HO-2 proteins are constitutively expressed. HO-3 protein expression awaits further characterization. HO-2 transcription is only up-regulated by few agents, such as opiates and adrenal glucocorticoids (Li and David Clark, 2000; Liu et al., 2000).
HO-1 gene expression is highly inducible by more diverse stimuli than any other enzyme described to date (Maines, 1997) and involves a multitude of signaling pathways (Table 2) (Immenschuh and Ramadori, 2000). HO-1 expression is mainly regulated at the transcriptional level.
|
Since HO-1 gene expression is strongly induced by agents or conditions that increase oxidative stress, redox signaling plays a crucial role in its regulation. These stimuli include heavy metals, bacterial lipopolysaccharides, hypoxia, hyperoxia, heat shock, ischemia, UV radiation, H2O2, cytokines, nitric oxide, stimuli that deplete cellular glutathione stores, and its substrate heme (Applegate et al., 1991; Shibahara, 1994; Immenschuh and Ramadori, 2000). In addition, several different redox-independent signaling pathways are involved in HO-1 gene regulation (Immenschuh and Ramadori, 2000). These include kinases [e.g., mitogen-activated protein kinases (Elbirt et al., 1998; Oguro et al., 1998), protein kinase C (Alam et al., 1995; Terry et al., 1999), cAMP-dependent protein kinase A (Immenschuh et al., 1998), and cGMP-dependent protein kinase G(Polte et al., 2000)] and protein phosphatases (Immenschuh et al., 2000). However, HO-1 gene expression is often cell type- and species-specific (Morse and Choi, 2002).
Consistent with the diversity of signaling cascades involved in HO-1 induction, the promoter region of HO-1 contains a wide variety of regulatory elements (Abraham et al., 1996). It includes DNA-binding sites for oxidative stress-responsive transcription factors, such as nuclear factor (NF)-
B, NF-E2-related factor 2 (Nrf2), and AP-1 (Lavrovsky et al., 1994; Choi and Alam, 1996).
Next to inducers of HO-1, negative regulators also exist, e.g., scavengers of ROS, such as N-acetylcysteine that reduce the magnitude of HO-1 induction by oxidative stress (Lautier et al., 1992). Furthermore, it has been reported that the HO-1 gene is further down-regulated by angiotensin II via calcium-signaling (Ishizaka and Griendling, 1997), interferon-
(Takahashi et al., 1999), prostaglandin E2 (Tetsuka et al., 1995), transforming growth factor-
(Pellacani et al., 1998), and IL-10 (Immenschuh et al., 1999).
HO-1 is active even at low substrate concentrations, and its activity increases as the concentration of heme increases within the physiological range. In contrast, HO-2 has low activity at low substrate concentrations, and even its maximum activity is limited to less than 10% that of HO-1 (Table 1) (Maines and Panahian, 2001). However, the enzymatic activity of HO-2 can be increased in a protein kinase C-dependent manner (Dore et al., 1999).
Specific activity of HO in different organs greatly varies. The highest HO activity is found in spleen, testis, and brain. The spleen is the only organ in which under normal unstressed conditions, HO-1 is the predominant form. HO-2 is abundant in brain, testis, and liver. HO-3 has been identified in brain, kidney, liver, heart, testis, and spleen and has been reported to have only very poor heme degrading capacity (McCoubrey et al., 1997).
Because of their heme-binding capacity, HO-2 and HO-3 may function as a first buffer reservoir for sudden accumulation of free heme. Similarly, other heme proteins may not only exert their specific activity but may also have a function in restraining free heme from exerting injurious effects (Nath et al., 2000). Moreover, there are several specialized heme-binding proteins (HBP) present in a cell, such as L-FABP, glutathione S-transferase, heme-binding protein 23 (HBP23), and p22 HBP, HO-2, HO-3) (Immenschuh et al., 1995). Although, the exact function of HBPs remains unclear, they are likely involved in shielding from oxidative assaults, heme trafficking, and heme utilization for heme protein synthesis.
Interestingly, expression of CD163, a hemoglobin/haptoglobin scavenger receptor on macrophages, is highly up-regulated by acute phase reactants, such as interleukin-6 (IL-6) and glucocorticoids (Buechler et al., 2000; Hogger and Sorg, 2001; Kristiansen et al., 2001). Haptoglobin, CD163, and HO-1 may be regarded as a "scavenger molecule-receptor-enzyme" system that is coherently elevated during inflammatory conditions to enhance the capacity for hemoglobin clearance (Kristiansen et al., 2001).
C. Traditional View on Heme Oxygenase and Its Toxic Breakdown Products
Traditionally, HO has been thought to be solely involved in the breakdown of heme from senescent red blood cells or denatured heme proteins. The degradation products free iron, biliverdin/bilirubin, and CO produced during this useful process were considered "toxic waste" materials (Johnson et al., 1999).
Free iron(II) (Fe2+) is capable of causing severe oxidative stress by the generation of reactive molecules, such as the highly reactive hydroxyl radical, since it can participate in Fenton reaction, which involves H2O2 and iron reacting with a variety of organic molecules, resulting in a series of radical reactions (Tyrrell, 1999; Alayash et al., 2001). This oxidative stress might then result in membrane damage and consequently tissue injury. Iron is thus generally considered a powerful prooxidant and injurious to cells.
The heme breakdown product biliverdin is rapidly reduced to bilirubin by the cytosolic enzyme biliverdin reductase. Reduction of biliverdin to bilirubin occurs in all mammals, but in some non-mammals, such as birds, amphibians, and reptiles, biliverdin is the end product of heme catabolism and is excreted in e.g., egg shells and manure (Lane, 1998). Since bilirubin is highly lipophilic, it is excreted as the glucuronide conjugate. The increased water solubility of bilirubin diglucuronide facilitates its excretion with bile as the bile pigments.
Bilirubin production is two to three times elevated in newborns compared with normal adults, because of the switching from fetal to adult hemoglobin (Maines and Trakshel, 1992). Approximately 5% of newborns suffer from neonatal jaundice, or hyperbilirubinemia. If the bilirubin levels become dangerously high, bilirubin passes through the blood-brain barrier and can cause neuronal damage associated with kernicterus (Gourley, 1997). The most common treatment for hyperbilirubinemia is phototherapy, in which the jaundiced infant is exposed to blue light. The therapeutic effect is mediated by photoisomerization of unconjugated bilirubin, resulting in more polar and readily excretable photoisomers (McDonagh and Lightner, 1985). Recently, alternative treatment with competitive inhibitors of HO activity, such as stannic mesoporphyrin (single dose of 6 µmol/kg), has shown to prevent and to reverse bilirubinemia (Kappas et al., 1995a, 2001).
CO has been considered a dangerous poisonous gas for a long time (Johnson et al., 1999). It is usually generated during the incomplete burning of organic materials. Bernard reported already in 1857 that CO could bind to hemoglobin. In fact, this odorless, colorless, tasteless gas binds about 200 times better to hemoglobin than oxygen, resulting in the formation of carboxyhemoglobin. This subsequently results in decreased oxygen release to the metabolizing tissues and ultimately death (Johnson et al., 1999). CO was shown to be an endogenous metabolic product in man by Sjoestrand (1949), who also observed that the rate of CO production was elevated in patients with increased destruction of erythrocytes (Sjoestrand, 1949a,b). The hypothesis that heme is the source of endogenous CO production in mammals was confirmed in vivo by investigators who used radioactive tracers to show that the -meso carbon of heme is oxidized to CO and bilirubin (Coburn et al., 1967). The rate of CO production in the human body is normally approximately 16 µmol/h (Marks, 1994), but it can get 10-fold higher in pathological circumstances, such as hemolysis (Coburn et al., 1966).
D. Recent Insights in Heme Oxygenase and a Novel Role for Heme-Derived Metabolites
In addition to the role of HO in recycling iron for heme synthesis, current understanding of HO has demonstrated that HO is important in a wide variety of other physiological and pathological processes. To date, no other known enzyme is induced by so many stimuli of diverse origin as HO-1 (Maines, 1997; Otterbein and Choi, 2000) (Table 2). It is this diversity of non-heme inducers and the existence of different HO isoforms that has led to the hypothesis that HO-1 plays a vital function in maintaining cellular homeostasis in addition to heme degradation (Maines, 2000).
Elevated HO-1 expression levels are detected in a variety of pathological conditions (Otterbein and Choi, 2000) (Table 3). HO-1 induction protects against ischemia/reperfusion injury, oxidative stress, inflammation, transplant rejection, apoptosis, and many more conditions (Amersi et al., 1999; Yang et al., 1999; Brouard et al., 2000, 2002; Willoughby et al., 2000; Inguaggiato et al., 2001; Sato et al., 2001; Ke et al., 2002; Melo et al., 2002). Although the precise mechanism is poorly understood and requires further investigation, consensus has been reached about the potent cytoprotective properties of HO-1.
|
Previous studies demonstrated that the induction of HO-1 induction is accompanied by increased ferritin synthesis, whereas inhibition of HO activity causes a decrease in ferritin levels (Eisenstein et al., 1991; Vile et al., 1994). Chelating iron prevents ferritin synthesis and fails to protect against iron-mediated oxidative stress (Otterbein et al., 1997). In contrast, HO-dependent release of iron results in up-regulation of ferritin, scavenging of the free iron, and subsequently protection from the adverse effects of iron. Each apo-ferritin molecule of 450 kDa can sequester up to approximately 4,500 iron atoms (Harrison and Arosio, 1996). Maintenance of low iron pools by increased ferritin levels appears to play a central role in cellular anti-oxidant defense and cytoprotection (Torti and Torti, 2002).
In addition, HO-1 is closely associated with cellular iron extrusion mechanisms, which may constitute an alternative cytoprotective mechanism of HO-1 (Snyder and Baranano, 2001). Attenuated HO-1 activity results in decreased cellular iron efflux and subsequently iron overload, whereas HO-1 overexpression accelerates efflux (Poss and Tonegawa, 1997a; Ferris et al., 1999). Baranano et al. (2000) demonstrated that HO-1 decreases intracellular levels of free (unbound) iron by up-regulating an iron ATPase present in the endoplasmic reticulum that can pump iron out. Interestingly, iron regulates nuclear transcription of several other genes as well, such as inducible NOS (iNOS), transferrin, and HO-1 (Abraham et al., 1988; Siow et al., 1999; Baranano et al., 2002).
Bilirubin was only recently recognized as a potentially important anti-oxidant of physiological significance (Stocker et al., 1987), although this property had already been known for some time (Bernard et al., 1954). Administration of bilirubin demonstrated to be cytoprotective in models of ischemic heart injury and oxidative damage (Dore et al., 1999; Clark et al., 2000). It was shown in vitro that at micromolar concentrations both biliverdin and bilirubin efficiently scavenge peroxyl radicals, thereby inhibiting lipid peroxidation (Stocker et al., 1987). In liposomes, bilirubin suppressed oxidation even more effectively than -tocopherol or vitamin E, which are regarded as excellent anti-oxidants (Stocker et al., 1987). These results indicate that bilirubin functions as a very prominent anti-oxidant in human serum and provides potent protection against oxidative injury and inflammation and decreases risk for familial coronary artery disease (Gopinathan et al., 1994; Hopkins et al., 1996).
CO had no known physiological function until Marks and coworkers proposed that CO may play a role similar to nitric oxide (NO) in signal transduction (Marks et al., 1991). During the last decade, NO research has taken a prominent position into the pathogenesis of virtually all diseases. NO signaling prevents hypertension, ameliorates inflammation, and functions as an important messenger molecule (Ignarro, 1996).
However, NO has not been able to fulfill the high expectations (Lane, 1998). The efficacy is hampered by the fact that NO is a reactive nitrogen species (RNS). Under oxidative conditions, NO reacts with other ROS resulting in the formation of the highly reactive ONOO- (peroxynitrite) (Wolin et al., 1998). Peroxynitrite does not prevent or ameliorate disease states like NO but, in contrast, exacerbates oxidative and inflammatory stress.
CO, in contrast to NO, does not contain free electrons and is therefore relatively inert. Moreover, this simple molecule shares the ability of NO to activate the heme protein guanylyl cyclase by binding to its active site, the heme molecule, resulting in enhanced conversion of guanosine triphosphate (GTP) to guanosine 3,5-cyclic monophosphate (cGMP) and subsequently vasodilation (Marks et al., 1991; Morita and Kourembanas, 1995; Maines, 1997). CO can activate this second messenger system and thereby mediate numerous physiological processes, such as activities of protein kinases, ion channels, and phosphodiesterases (Maines, 1997). Interestingly, NO and peroxynitrite induce HO-1 activity and thus form a feedback loop, where CO takes over the roles of NO under conditions of oxidative stress (Maines, 1997). Therefore, HO activity is important in controlling the activity of heme proteins, such as cytochromes P450, COX, guanylyl cyclase, and NOS, not only at the level of the intracellular heme pool available for the apo-heme proteins (Kappas and Drummond, 1986) but possibly also at the level of HO's downstream effector molecule CO by interactions with the heme group (Haider et al., 2002).
It has been shown that exogenous CO (ca. 300 parts per million) reduces inflammatory responses in several models of oxidant injury, which is consistent with results observed with HO-1 overexpression (Abraham et al., 1995a; Amersi et al., 1999). Although CO acts in many ways that are similar to NO, CO possesses additional functions on signal transduction pathways. CO inhibits pro-inflammatory genes while augmenting antiinflammatory cytokine production by selective activation of several p38 mitogen-activated protein kinase (MAPK) signaling pathways in a guanylyl cyclase-independent manner (Brouard et al., 2000; Otterbein et al., 2000; Sarady et al., 2002; Song et al., 2003).
Other important effects of CO involve inhibition of proliferation of vascular smooth muscle cells, inhibition of platelet aggregation, protection against apoptosis, and acting as a neurotransmitter (Brune and Ullrich, 1987; Durante and Schafer, 1998; Brouard et al., 2000; Togane et al., 2000; Baranano and Snyder, 2001). Therefore, although high amounts of CO are lethal, low concentrations of CO mediate many important physiological functions, such as maintenance of vasomotor tone and mediating neurotransmission (Johnson et al., 1999).
In summary, although the mechanisms underlying the anti-inflammatory actions of HO-1 remain unclear, the heme-degradation products CO, biliverdin/bilirubin, and iron-induced ferritin seem to be mediators of the beneficial effects of HO-1 activation. CO causes vasodilation, inhibits platelets aggregation, and suppresses the production of cytokines, whereas alternative actions could be exerted by the potent anti-oxidant properties of biliverdin/bilirubin and the iron-capturing actions of ferritin (Maines, 1997; Otterbein and Choi, 2000).
|
IV. Inflammation and the Role of Adhesion Molecules |
|---|
|
TopPreviousNext |
|---|
An essential step of the leukocyte-adhesion cascade involves a series of sequential activation and adhesion events. This cascade requires the activation of endothelial cells resulting in highly increased surface expression of specific inflammatory adhesion molecules (Table 4), such as selectins, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule (VCAM-1), enabling circulating activated leukocytes to specifically interact with their ligands on the endothelium. Next, capture, rolling, and firm adhesion of leukocytes is followed by transmigration through the endothelium toward the site of injury by chemotaxis. Here they exert their effector functions and eradicate the source of inflammation (Fig. 5).
|
|
Although inflammation is an essential and beneficial process in the protection against pathogens, occasionally the inflammatory process is directed against autologous antigens, or the process does not alleviate after its onset and escalates into long-term persistence of inflammation, i.e., chronic inflammation (Robbins et al., 1999). The excessive release of proteases and ROS by the activated leukocytes and endothelial cells in these conditions can ultimately result in severe tissue damage (Conner and Grisham, 1996). In the pathogenesis of several diseases, such as rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, multiple sclerosis, Alzheimer disease, and transplant rejection, inflammation-mediated tissue injury plays an important role (Cotran and Mayadas-Norton, 1998).
In many inflammatory diseases, currently available intervention strategies fail or are of limited success. Therefore, there is a great need for novel strategies to treat chronic inflammatory conditions. One approach could be to control adhesion molecule expression, which is pivotal in the outcome of inflammatory processes (Behrend, 2000).
A. The Role of Heme in Inflammation
Large amounts of free heme and heme proteins are found after hemolysis or rhabdomyolysis in various pathological conditions, including ischemia/reperfusion, hemoglobinopathies, hematoma, hemorrhage, and muscle injury (Letarte et al., 1993; Nath et al., 1998, 2001a; Alayash, 2000) (Fig. 3).
Heme-mediated oxidative insults and inflammation are likely important in a wide variety of pathophysiological processes (Balla et al., 2000). Heme and heme proteins have been implicated in vasospasm, vasoconstriction, oxidative stress, and endothelial cell adhesiveness, whereas a variety of toxic effects are attributed to oxidized lipids (Letarte et al., 1993; Wagener et al., 1997; Balla et al., 2000; Lavrovsky et al., 2000).
We previously demonstrated that elevated levels of heme can act pro-inflammatory. We observed that heme induces the expression of pro-inflammatory adhesion molecules both in vitro (Wagener et al., 1997) and in vivo (Wagener et al., 2001b). Moreover, vascular heme was also found to promote an increase in vascular permeability and the infiltration of leukocytes into a variety of tissues in a mouse model (Wagener et al., 2001b).
Nath et al. (2001b) demonstrated in a kidney model that heme proteins elicit inflammatory processes. Heme proteins, such as hemoglobin, get stuck in the glomeruli and accumulate in the kidney. Based on our observations, subsequent release of heme may then result in local inflammatory reactions and ultimately lead to renal failure. In fact, they observed an increased expression of monocyte chemoattractant protein (MCP-1) upon exposure to heme proteins. This finding adds significantly to our understanding of the observed heme-induced leukocyte recruitment.
Several groups have reported that the efficacy of artificial blood substitutes, such as modified hemoglobin solutions, are often hampered by oxidative and inflammatory complications (Simoni et al., 1997; Goldman et al., 1998; Baldwin, 1999). This phenomenon may be related to a difference in heme-releasing capacity of the different hemoglobin solutions. Upon release from hemoglobin, heme interacts with the vascular wall and induces oxidative stress, adhesion molecule expression, and vasopermeabilization (Wagener et al., 1997, 2001b).
Furthermore, the demonstrated vaso-occlusion and vascular inflammation present in several hemoglobinopathies are thought to be caused by increased adhesive interactions between the vascular endothelium and circulating blood cells (Moore et al., 1996; Hebbel, 1997; Solovey et al., 2001). In sickle cell disease, accumulation of heme, adhesion molecule expression, and an increased risk of renal failure have recently been demonstrated (Shiu et al., 2000; Nath et al., 2001a; Bonaventura et al., 2002; Frenette, 2002), strengthening the idea that heme-induced oxidative and inflammatory insults relate to its etiology (Wagener et al., 2001a).
B. Consequences of Heme-Induced Oxidative Stress and Inflammation
These recent observations may have widespread implications for the understanding of various inflammatory complications. It implicates, on the one hand, that at sites of injury, the released heme may be a physiological response that is necessary to recruit inflammatory cells, to initiate inflammatory processes, and to function as a first "danger signal". However, on the other hand, excess of free heme may cause oxidative and inflammatory injury. In that case, it is of utmost importance to shield the oxidative and inflammatory properties of free heme; e.g., prevention of the formation of methemoglobin, which easily releases its heme, may be helpful in the design of safe "blood substitutes".
This adds to the hypothesis that heme-induced inflammation is involved in the pathology of diverse conditions, such as renal failure, atherosclerosis, complications after artificial blood transfusion, peritoneal endometriosis, and heart transplant failure (Jacob, 1994; Nath et al., 1995; Alayash, 2000; Sato et al., 2001; Van Langendonckt et al., 2002).
Based on our findings, it seems important that packed red blood cells should be first washed before administration to a patient to prevent inflammatory complications during blood transfusions, since during storage a significant amount of erythrocytes will have been lysed, resulting in large amounts of free heme that may initiate inflammation. Alternatively, patients with increased vascular free heme, e.g., after intravascular hemolysis, may benefit from plasmapheresis or dialysis to dilute its potential damaging activities.
Furthermore, appearance of functional relevant polymorphisms for haptoglobin, hemopexin, and HO could be important for people with increased risk of heme release or people with already compromised redox balance, such as diabetes patients, sports people, or people undergoing transplantation or surgery. In case these individuals have a compromised protection against heme and heme protein-mediated inflammation priming of HO-1 expression or administration of heme/hemoglobin scavengers may protect them from injury.
For the hemoglobin scavenger, haptoglobin, there have been three major polymorphisms described that are associated with different prevalence of many inflammatory diseases, including infections, atherosclerosis, and autoimmune disorders (Langlois and Delanghe, 1996). Interestingly, these different polymorphisms possess also different hemoglobin-scavenging activity (Wuyts et al., 2000). Moreover, the carriers of the polymorphisms that are severely impaired in hemoglobin binding show to be more susceptible to cardiovascular diseases, such as atherosclerosis (Braeckman et al., 1999). This may possibly be explained by our findings of heme-mediated oxidative and inflammatory effects, such as foam cell formation, adhesion molecule expression, and leukocyte recruitment (Wagener et al., 2001b, 2003b). Interestingly, both polymorphisms in haptoglobin and HO-1 are considered risk factors for restenosis after percutaneous transluminal angioplasty (Exner et al., 2001; Roguin et al., 2001).
C. The Role of Heme Oxygenase in Inflammation
In 1916, Suzuki postulated the idea that prior exposure to toxins induces resistance to secondary toxic insults, although the mechanism for this protection remained unclear (Platt and Nath, 1998). Keyse and Tyrrell (1989) were the first to assume that up-regulation of HO-1 by stress-causing agents could mediate this protection against subsequent noxious stimuli (Keyse and Tyrrell, 1989). The stress protein HO-1 is up-regulated by a wide range of stress signals, including cytokines, heavy metals, and also by its substrate heme (Maines, 1997). This illustrates the different faces of the heme molecule in inflammation; small concentrations of heme act cytoprotective via the swift up-regulation of HO-1 (Hayashi et al., 1999), whereas large amounts of heme may act deleterious on tissue via its pro-oxidative and pro-inflammatory functions (Nath et al., 2001b; Wagener et al., 2001b), which cannot be neutralized anymore by the anti-oxidative and anti-inflammatory properties of the HO-1 end-products. Moreover, the time kinetics of HO-1 expression in relation to the inflammatory insult is important for the pro-inflammatory potency of heme and other mediators.
The evolving paradigm of HO-mediated protection of cells and tissues is supported by several animal models of oxidant injury (endotoxic shock, ischemia, hyperoxia, etc.) and acute inflammation (Hancock et al., 1998; Otterbein et al., 1999a; Li et al., 2000; Tamion et al., 2001). In these models, HO-1 elevation confers potent resistance to stress, cell injury, and lipopolysaccharide-induced death whereas blocking of HO activity abrogates cytoprotection, resulting in severe tissue damage. In addition, increased HO-1 expression levels have clinically been demonstrated in a wide variety of inflammatory conditions, such as ischemia/reperfusion injury, atherosclerosis, asthma, Alzheimer disease, and acute renal failure (Amersi et al., 1999; Siow et al., 1999; Agarwal and Nick, 2000; Maines, 2000; Tullius et al., 2001). Moreover, HO-1 production is greatly elevated in inflammatory cells during the resolution phase of inflammation (Fig. 6) (Willis et al., 1996). Very recently, it has been suggested that IL-10, a key molecule for controlling inflammation, mediates many of its anti-inflammatory effects via up-regulation of HO-1 (Lee and Chau, 2002). Induction of HO-1 corresponds to a significant suppression of inflammation, whereas inhibition of the enzyme potentiates the inflammatory response in several models of inflammation (Amersi et al., 1999; Nath, 1999; Vogt et al., 1996; Agarwal and Nick, 2000; Willis et al., 2000; Wagener et al., 2001b). These include corneal, lung, and renal inflammatory models, and in transplantation biology (Laniado-Schwartzman et al., 1997; Platt and Nath, 1998; Otterbein et al., 1999a; Agarwal and Nick, 2000).
|
D. Mechanism of Heme Oxygenase-Mediated Down-Modulation of Inflammation
To date, the mechanism by which HO-1 functions as a cytoprotective and anti-inflammatory protein remains poorly understood. Based on our data, which is in line with observations of others, we postulate that one mechanism by which HO exerts its cytoprotective effects is mediated by down-modulation of adhesion molecule expression. It is evident that adhesion molecules are important to recruit inflammatory cells to sites of acute and chronic inflammation and are therefore crucial in determining the outcome of the inflammatory process (Behrend, 2000). This hypothesis is supported by our observations that HO-1 overexpression reduces heme-induced ICAM-1 expression, whereas inhibition of HO activity increases heme-induced ICAM-1 expression and leukocyte influx (Wagener et al., 1999, 2001b).
Moreover, it has now been confirmed by several other laboratories that HO-1 up-regulation ameliorates adhesion molecule expression and leukocyte adhesion in several other models of inflammation, whereas inhibition of HO activity exacerbates adhesion molecule expression both in vitro and in vivo (Hayashi et al., 1999; Vachharajani et al., 2000; Rucker et al., 2001).
Hayashi et al. (1999) demonstrated that HO-1 induction down-modulates H2O2-mediated induction of P-selectin and subsequently decreases leukocyte binding in vivo, whereas Rucker et al. (2001) observed in vivo decreased ICAM-1 expression in a model of arterial injury when HO-1 was up-regulated prior to injury. This model may thus provide a plausible molecular basis for the previously reported anti-inflammatory properties of HO-1.
The HO-2 and HO-3 isoforms probably function normally as first defense against oxidative/inflammatory insults, whereas upon stress HO-1 is swiftly up-regulated and strongly protects against further injurious signals. HO-2, which is highly expressed in brains and testis, protects, e.g., neurons against oxidative stress. HO-2 may function as a physiologic regulator of cellular function, whereas HO-1 plays a role in modulating tissue responses to injury in pathophysiologic states (Wagener et al., 1999).
Adhesion molecule expression can be down-regulated by anti-oxidants and the gaseous mediator NO (De Caterina et al., 1995; Berendji-Grun et al., 2001). HO activity may decrease adhesion by depleting heme and generating anti-oxidants biliverdin/bilirubin and the gaseous signaling molecule CO, which shares many properties with NO. Unfortunately, under oxidative circumstances, NO is converted into peroxynitrite, which possesses pro-inflammatory properties (van Der Vliet et al., 2000). However, both NO as peroxynitrite up-regulate HO-1 expression (Foresti et al., 1999; Liang et al., 2000). The hereby generated CO has now been postulated to take over the role of NO under oxidative conditions (Foresti and Motterlini, 1999).
Pro-inflammatory mediators, like TNF- and heme, activate the transcription factors NF-B, AP-1, and SP-1 signaling pathways via the formation of ROS, which may result in the transcriptional activation of several genes involved in inflammation, such as ICAM-1, VCAM-1, and selectins (Lavrovsky et al., 1994; Shono et al., 1996).
Interestingly, the HO effector molecules biliverdin/bilirubin and CO have also been implicated in the modulation of a range of signaling pathways, including the cGMP and MAPK system, by which they may modulate inflammatory processes and also be involved in ROS-mediated signaling (Adeagbo, 1997; Siow et al., 1999; Otterbein et al., 2000; Nath et al., 2001b). It is likely that HO effector molecules bilirubin and CO, similar to anti-oxidants and NO (De Caterina et al., 1995), play a role in the regulation of ROS-mediated pathways, since HO-1 knockout mice show increased nuclear staining of NF-B after exposure to hemoglobin, compared with control mice (Nath et al., 2001b).
E. Effects of Heme Oxygenase Inhibition versus Heme Oxygenase-1 Overexpression
The observation that both large amounts of free vascular heme as well as oxidative and chronic inflammatory complications and a remarkable sensitivity to stressful assaults in the first known human case of HO-1 deficiency (Yachie et al., 1999; Kawashima et al., 2002) is consistent with data from our mouse model (Wagener et al., 2001b). This boy who died at age 6 suffered from growth retardation, anemia, leukocytosis, thrombocytosis, coagulation abnormality, elevated serum levels of haptoglobin, ferritin, and heme, a low serum bilirubin concentration, and hyperlipidemia (Yachie et al., 1999; Kawashima et al., 2002). Autopsy revealed the presence of amyloid deposits, foamy macrophages, fatty streaks, and fibrous plaques. Interestingly, it was observed that endothelial ICAM-1 and Von Willebrand factor were highly increased in this patient, which supports our findings in mice (Wagener et al., 2001b; Kawashima et al., 2002).
These findings in human are paralleled by similar phenotypic data obtained from HO-1 targeted (HO-1 -/-) mice (Nath et al., 2001b; Poss and Tonegawa, 1997a,b). These knockout mice are characterized by anemia, tissue iron depositions, and severe inflammatory conditions, such as enlarged spleen and lymph nodes, hepatic inflammatory cell infiltrates, vasculitis, and glomerulonephritis (Poss and Tonegawa, 1997a). These mice are also extremely sensitive to oxidative injury and to endotoxin-mediated cell death (Poss and Tonegawa, 1997b). Furthermore, they express growth retardation and are prone to abortions (Poss and Tonegawa, 1997a).
HO-2-derived CO plays an important role in the neurotransmitter control and in activation of guanylyl cyclases, in conjunction with NO. Mice targeted in HO-2 demonstrate important abnormalities in the central and peripheral nervous systems as exemplified by interference with ejaculation (Burnett et al., 1998).
Overexpression of HO-1 can lead to hyperbilirubinemia in humans with certain hepatic disorders especially in patients in whom bilirubin disposition is impaired for developmental or genetic reasons, e.g., in newborns and in patients with the Crigler-Najjar Type I syndrome (Kappas et al., 1993). Drummond and colleagues have shown that pharmacological agents such as the inhibitor of HO, stannic mesoporphyrin, can inhibit HO activity significantly and is highly effective in a single dose in controlling hyperbilirubinemia (Martinez et al., 2001) (personal communication). However, such agents can exert only transient control of the activity of HO-1. Furthermore, the long-term overexpression or inhibition of different HO isoforms would have considerable experimental value in elucidating the role of the enzyme in physiological and pathological processes.
Quan et al. (2001) examined the feasibility of utilizing the retrovirus-mediated transfer of a human HO-1 (hHO-1) sense (S) and antisense (AS) orientation sequence under the control of the hHO-1 promoter to regulate endogenous HO-1 expression and function and thus permit development of gene transfer technology to regulate the rate of heme catabolism over the long term (Quan et al., 2001). Their data demonstrate for the first time that selective delivery of the hHO-1 gene in antisense orientation into human endothelial cells results in an attenuation of hHO-1 protein leading to a decrease in the rate of catabolism of cellular heme and that this effect is brought about without altering endogenous HO-2 protein.
Thus by using retroviral HO-1 antisense methodology, it is possible to envisage prolonged down-regulation of the rate of heme catabolism to its degradation product bilirubin in clinical or experimental circumstances where this might prove useful. Alternatively, inhibition of HO isoforms may be established using RNA interference techniques.
In contrast, the development of gene transfer techniques has provided the opportunity to deliver a functional HO-1 gene and to evaluate the direct effects of this gene on, e.g., vascular functions.
Using a retroviral vector, Sabaawy et al. (2001) established chimeric rats expressing the human HO-1 gene to study hypertension. Surprisingly, they observed that these rats, in addition to developing decreased blood pressure, grew significantly faster than rats lacking the hHO-1 gene, particularly during the first 12 weeks. Importantly, the increase in somatic growth associated with hHO-1 expression in rats was both proportionate and not associated with an increase in food intake. Interestingly, both human (Yachie et al., 1999) and mice (Poss and Tonegawa, 1997a) lacking the HO-1 gene display severe growth retardation.
An alternative means of establishing HO isoform overexpression is the use of TAT-HO proteins. The fusion protein of HO-1 to an 11-amino acid cell-penetrating peptide from the human immunodeficiency virus TAT protein enables efficient HO-1 protein entry and proved to protect pancreatic -cells against TNF--mediated injury (Ribeiro et al., 2003).
The importance of a fine balance of the heme-HO system is further underscored by accumulating data demonstrating that induction of HO-1 by gene transfer protects cells from hemoglobin/heme-mediated oxidative stress, leukocyte infiltration, and against a range of inflammatory complications, such as ischemia/reperfusion injury and hyperoxia-induced injury (Abraham et al., 1995b; Amersi et al., 1999; Yang et al., 1999). Moreover, it has recently been found that HO-1 gene transfer protects blood vessels from pathological vasoconstriction and excessive smooth muscle cell proliferation in animal models of arterial injury (Duckers et al., 2001). Furthermore, HO-1 transgenic mice are protected from hypoxia-induced inflammation and vascular dysfunction (Minamino et al., 2001).
Interestingly, HO-1 has been shown to interact with cellular and synthetic proteins, which may modulate the activity of the enzyme. Interactions with amyloid precursor proteins, which are implicated in the pathogenesis of Alzheimer disease, have been demonstrated to inhibit HO-1 activity, resulting in a compromised stress defense (Takahashi et al., 2000; Takahashi and Snyder, 2000; Wagener et al., 2003b). On the other hand, Buelow and colleagues have demonstrated that the synthetic peptide RDP1258 can bind HO-1 and cause increased HO-1 expression and activity in vivo (Cuturi et al., 1999; Magee et al., 1999). This protein has further shown to be highly effective in ameliorating a range of inflammatory conditions (Cuturi et al., 1999; Oberyszyn et al., 2001).
Thus, HO seems to be cytoprotective by limiting the influx of activated inflammatory cells and by ameliorating the extent of cellular necrosis and apoptosis in injured tissues. On the other hand, too high HO-1 expression may also cause tissue injury by the generation of high levels of iron or result in bilirubinemia (Suttner and Dennery, 1999).
|
V. The Heme-Heme Oxygenase System |
|---|
|
TopPreviousNext |
|---|
; Maines, 2000; Wagener et al., 2003a). A. The Heme-Heme Oxygenase-1 System and Apoptosis
Under oxidative and inflammatory conditions necrosis and apoptosis may occur, which result in the release of large amounts of heme and subsequently exacerbation of the inflammatory process and cellular injury. However, under these conditions the stress-responsive protein HO-1 will be immediately induced as well.
A growing body of evidence suggests that expression of HO-1 acts in an anti-apoptotic manner in several cells types. This was originally demonstrated by the observation that overexpression of HO-1 in endothelial cells protected these cells from TNF--mediated apoptosis (Soares et al., 1998). In a similar manner, overexpression of HO-1 has also been shown to protect fibroblasts from TNF--mediated apoptosis (Petrache et al., 2000). Subsequently, Ferris et al. (1999) showed that the antiapoptotic action of HO-1 was associated with the expression of an iron pump, which is responsible for the decrease of intracellular iron content. This may relate to the anti-apoptotic effect of HO-1 because by decreasing iron content cells would become less likely to generate ROS through the Fenton reaction. Given the critical role of ROS generation in the induction of signal transduction pathways that lead to apoptosis, cells that have decreased levels of ROS would become protected from undergoing apoptosis. These authors also suggested that CO does not mediate the anti-apoptotic effects of HO-1 (Ferris et al., 1999). This assumption was largely based on the observation that activation of guanylyl cyclase and/or generation of cGMP (which occur when CO is generated) does not protect cells from undergoing apoptosis (Ferris et al., 1999). Although this observation is also true in other cell types such as endothelial cells, recent work from Brouard et al. (2000) have shown that whereas the cGMP pathway is not involved in the antiapoptotic action of HO-1, CO can mediate the anti-apoptotic effect of HO-1 via the activation of the p38 MAPK signal transduction pathway in endothelial cells. It should be noted that, as for endothelial cells, CO can also mediate anti-apoptotic effects in fibroblasts. However, in fibroblasts the protective effect of CO occurs through a mechanism that is dependent on the activation of guanylyl cyclase and the generation of cGMP but independent of the activation of the p38 MAPK signal transduction pathway (Petrache et al., 2000). In other cells types, such as in -cells of pancreatic islets, CO exerts anti-apoptotic effects through a mechanism that requires both the activation of the cGMP and the p38 MAPK signal transduction pathways.
These observations indicate that the anti-apoptotic effect of CO can be mediated through the modulation of different signal transduction pathways depending on the cell type. The mechanism by which HO-1 and/or CO act to protect cells from undergoing apoptosis is not yet clear. Recently, Brouard et al. (2002) have shown that the ability of HO-1 and/or CO to protect endothelial cells from TNF--mediated apoptosis is dependent on the activation of NF-B. Activation of this transcription factor promotes the expression of a series of anti-apoptotic genes, e.g., c-IAP2 and A1, that interact functionally with CO to prevent endothelial cell apoptosis (Brouard et al., 2002). More recently Duckers et al. (2001) have shown that expression of HO-1 induces the expression of the cyclin-dependent kinase inhibitor p21Cip1/Waf in smooth muscle cells whereas Inguaggiato et al. (2001) have shown that the same phenomenon occurs in renal epithelial cells. Interestingly p21Cip1/Waf expression confers resistance to apoptosis in several cell types and promotes the activation of NF-B (Polyak et al., 1996; Megyesi et al., 1998). This would indicate that the antiapoptotic effect of HO-1 and/or CO might be mediated through the expression of p21Cip1/Waf.
B. The Heme-Heme Oxygenase System and Transplantation Biology
The heme-HO system plays also a vital role in transplantation biology (Hancock et al., 1998; Sato et al., 2001). Graft rejection is a complex phenomenon that is associated with the induction of adhesion molecules in the graft endothelium, influx of immune cells, ischemia/reperfusion injury, and cell injury (Fuggle and Koo, 1998). Vascular dysfunction, immune cell influx, and arteriosclerosis are evident and ultimately result in organ rejection. It is tempting to speculate that the elevated release of denatured heme proteins, derived from injured cells, is of major importance in the initiation and progression of inflammation during the process of graft rejection.
Interestingly, in several transplantation models, HO-1 has been demonstrated to play an indispensable role in terms of promoting graft survival. Elevated HO activity prevents the development of vascular lesions, intragraft apoptosis, ischemia/reperfusion injury, and significantly prolongs allograft survival (Hancock et al., 1998; Soares et al., 1998; Pileggi et al., 2001; Tullius et al., 2001; Katori et al., 2002). Moreover, in a model of xeno-transplantation, expression of HO-1 (Soares et al., 1998) and generation of CO (Sato et al., 2001) have been shown to suppress graft rejection and promote long-term graft survival. Under a given immunosuppressive regimen that allows the survival of wild-type mouse hearts transplanted into rat, mouse hearts lacking HO-1 expression (HO-1 -/-) are rejected (Soares et al., 1998). Given the above, it is tempting to postulate that injury-derived heme recruits leukocytes and promotes inflammation during transplant rejection, whereas HO activity prevents heme-induced inflammatory and oxidative actions. Presumably this effect of HO-1 acts through a complex mechanism that involves the down-modulation of adhesion molecules, subsequently preventing leukocyte recruitment and organ failure.
The increasing usage of "marginal" organs for transplantation because of the organ shortage brings new problems into transplant medicine. Organs from elderly donors suffering from diseases such as hypertony, hyperlipidemia, stroke, etc. are very sensitive to ischemia/reperfusion injury resulting in a higher risk for developing chronic graft injury. Very recently we could show that donor pretreatment with cobalt protoporphyrin 6 to 24 h before organ harvesting up-regulates HO-1 in the grafts and prevents both short-term and long-term ischemia/reperfusion injury of kidney allografts in normal donors as well as marginal donors. The kidney allograft recipients showed less proteinuria and improved histology and graft function even 6 months post-treatment. Interestingly, monitoring of intragraft gene expression suggests that the resistance of parenchymal graft cells to inflammation might be more important for the observed protection than down-regulation of inflammation by intragraft HO-1 up-regulation (Tullius et al., 2002).
C. The Heme-Heme Oxygenase System As Target for Inflammatory Control
The ultimate goal of research aimed at understanding inflammation is to develop methods to control inflammation in situations that are harmful to patients. In patients with increased inflammatory activity (e.g., chronic inflammation, rheumatoid arthritis, graft rejection), amelioration of inflammation is required, whereas in patients with a compromised immune system (e.g., cancer, AIDS), stimulation of the immune system is needed. An important role for the heme-HO system in the control of inflammation by modulation of cell adhesion can be envisioned (Fig. 6).
D. Some Considerations Concerning Modulation of the Heme-Heme Oxygenase System
Novel strategies in the control of inflammation may involve systemic administration of antisense oligonucleotides or antibodies against adhesion molecules, or antioxidants (Haller et al., 1996; Menger and Vollmar, 1996). Targeted expression of the inflamed tissue remains, however, difficult. A better understanding of the heme-HO system may result in novel therapeutic strategies to inflammatory diseases. HO-1 induction using gene therapy or pharmacological modulation show promising results both in vitro and in vivo (Yang et al., 1999; Duckers et al., 2001). The use of tissue-specific promoters would enable the generation of local vasorelaxants and anti-oxidants at places prone to inflammatory or oxidative insults. Alternatively, administration of solely the HO effector molecules bilirubin or CO seem to possess therapeutical value as well (Otterbein et al., 1999b; Chapman et al., 2001; Dennery et al., 2001). Bilirubin administration has been demonstrated to alleviate adhesion molecule expression, leukocyte binding, and to provide neuronal protection (Vachharajani et al., 2000). Furthermore, exposure to CO, or a synthetic precursor molecule of CO such as methylene chloride, prolongs allograft survival significantly.
It is important to take into account that the heme-HO system has regulatory functions in a wide variety of processes. Heme is the crucial part of many major enzymatic systems, such as nitric-oxide synthase, cytochrome P450, and COX (Maines, 1997). HO activity controls the activity of these heme proteins in at least two ways: directly, by regulating the availability of heme for the synthesis of heme proteins, or indirectly, via the generation of CO, which can bind to the heme moiety of heme proteins and thereby affecting their enzymatic activity (Fig. 6) (Haider et al., 2002).
Although HO-1 and its effector molecules, CO, biliverdin/bilirubin, and iron-ferritin, are nowadays recognized as cytoprotective agents, many of the effects of HO-1 are highly dependent on the redox state of the cell. Data from several laboratories demonstrated that directly after inducing HO-1, cells are sensitized to oxidative stress, whereas after prolonged time, ferritin is upregulated, and these cells are desensitized and significantly protected against a wide range of stresses (Balla et al., 1993; da Silva et al., 1996; Ryter and Tyrrell, 2000). It is evident that each of the heme breakdown products, when present in high quantities can mediate cell injury instead of cytoprotection (Fig. 3A) as described under Section III.C. (Suttner and Dennery, 1999). Whether the fine balance of the heme-HO-1 system mediates either cytoprotection or cytotoxicity is largely dependent on the microenvironmental circumstances. The sum of the anti-oxidative, pro-oxidative, and inflammatory signals within the surrounding tissue will probably determine the outcome. The understanding that the heme-HO system exerts a wide variety of functions, besides inflammatory control, is important when modulation of the system is considered as a potential therapeutic strategy.
|
VI. Conclusion |
|---|
|
TopPreviousNext |
|---|
|
Acknowledgements |
|---|
|
Footnotes |
|---|
Article, publication date, and citation information can be found at http://pharmrev.aspetjournals.org.
1 Heme is ferroprotoporphyrin IX; hemin is ferric protoporphyrin IX. In this review, the term heme is used as a generic expression denoting no particular iron valence state. 
2 Abbreviations: HO, heme oxygenase; AP-1, activator protein-1; COX, cyclooxygenase; HBP, heme-binding protein; hHO-1, human HO-1; HRE, heme-responsive element; ICAM, intercellular adhesion molecule; iNOS, inducible nitric-oxide synthase; MAPK, mitogen-activated protein kinase; MARE, Maf recognition element; MCP-1, monocyte chemoattractant protein 1; NF-B, nuclear factor-B; NO, nitric oxide; NOS, nitric-oxide synthase; RES, reticuloendothelial system; RNS, reactive nitrogen species; ROS, reactive oxygen species; TNF-, tumor necrosis factor-; VCAM, vascular cell adhesion molecule.
|
References |
|---|
|
Top |
|---|
Abraham NG (1991) Molecular regulation— biological role of heme in hematopoiesis. Blood Rev 5: 19-28.[CrossRef][Medline]
Abraham NG, da Silva JL, Lavrovsky Y, Stoltz RA, Kappas A, Dunn MW, and Schwartzman ML (1995a) Adenovirus-mediated heme oxygenase-1 gene transfer into rabbit ocular tissues. Investig Ophthalmol Vis Sci 36: 2202-2210.
Abraham NG, Drummond GS, Lutton JD, and Kappas A (1996) The biological significance and physiological role of heme oxygenase. Cell Physiol Biochem 6: 129-168.
Abraham NG, Friedland ML, and Levere RD (1983) Heme metabolism in hepatic and erythroid cells, in Progress in Hematology (Brown E ed) pp 75-130, Grune & Stratton, Inc. (G&S), New York.
Abraham NG, Lavrovsky Y, Schwartzman ML, Stoltz RA, Levere RD, Gerritsen ME, Shibahara S, and Kappas A (1995b) Transfection of the human heme oxygenase gene into rabbit coronary microvessel endothelial cells: protective effect against heme and hemoglobin toxicity. Proc Natl Acad Sci USA 92: 6798-6802
Abraham NG, Lin JH, Schwartzman ML, Levere RD, and Shibahara S (1988) The physiological significance of heme oxygenase. Int J Biochem 20: 543-558.[CrossRef][Medline]
Adeagbo AS (1997) Endothelium-derived hyperpolarizing factor: characterization as a cytochrome P450 1A-linked metabolite of arachidonic acid in perfused rat mesenteric prearteriolar bed. Am J Hypertension 10: 763-771.[CrossRef][Medline]
Agarwal A and Nick HS (2000) Renal response to tissue injury: lessons from heme oxygenase-1 GeneAblation and expression. J Am Soc Nephrol 11: 965-973.
Alam J, Camhi S, and Choi AM (1995) Identification of a second region upstream of the mouse heme oxygenase-1 gene that functions as a basal level and inducer-dependent transcription enhancer. J Biol Chem 270: 11977-11984.
Alayash AI (2000) Hemoglobin-based blood substitutes and the hazards of blood radicals. Free Radic Res 33: 341-348.[CrossRef][Medline]
Alayash AI, Patel RP, and Cashon RE (2001) Redox reactions of hemoglobin and myoglobin: biological and toxicological implications. Antioxid Redox Signal 3: 313-327.[CrossRef][Medline]
Amersi F, Buelow R, Kato H, Ke B, Coito AJ, Shen XD, Zhao D, Zaky J, Melinek J, Lassman CR, et al. (1999) Upregulation of heme oxygenase-1 protects genetically fat Zucker rat livers from ischemia/reperfusion injury. J Clin Investig 104: 1631-1639.[Medline]
Applegate LA, Luscher P, and Tyrrell RM (1991) Induction of heme oxygenase: a general response to oxidant stress in cultured mammalian cells. Cancer Res 51: 974-978.
Baldwin AL (1999) Modified hemoglobins produce venular interendothelial gaps and albumin leakage in the rat mesentery. Am J Physiol 277: H650-H659.
Balla G, Jacob HS, Eaton JW, Belcher JD, and Vercellotti GM (1991) Hemin: a possible physiological mediator of low density lipoprotein oxidation and endothelial injury. Arterioscler Thromb 11: 1700-1711.
Balla J, Balla G, Jeney V, Kakuk G, Jacob HS, and Vercellotti GM (2000) Ferriporphyrins and endothelium: a 2-edged sword-promotion of oxidation and induction of cytoprotectants. Blood 95: 3442-3450.
Balla J, Jacob HS, Balla G, Nath K, Eaton JW, and Vercellotti GM (1993) Endothelial-cell heme uptake from heme proteins: induction of sensitization and desensitization to oxidant damage. Proc Natl Acad Sci USA 90: 9285-9289.
Baranano DE, Rao M, Ferris CD, and Snyder SH (2002) Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci USA 99: 16093-16098.
Baranano DE and Snyder SH (2001) Neural roles for heme oxygenase: contrasts to nitric oxide synthase. Proc Natl Acad Sci USA 98: 10996-11002.
Baranano DE, Wolosker H, Bae BI, Barrow RK, Snyder SH, and Ferris CD (2000) A mammalian iron ATPase induced by iron. J Biol Chem 275: 15166-15173.
Barber A, Robson SC, Myatt L, Bulmer JN, and Lyall F (2001) Heme oxygenase expression in human placenta and placental bed: reduced expression of placenta endothelial HO-2 in preeclampsia and fetal growth restriction. FASEB J 15: 1158-1168.
Behrend M (2000) Immune-adhesion molecules in the prevention of allograft rejection and reperfusion injury. Expert Opin Investig Drugs 9: 789-805.[CrossRef][Medline]
Benz EJ Jr, Murnane MJ, Tonkonow BL, Berman BW, Mazur EM, Cavallesco C, Jenko T, Snyder EL, Forget BG, and Hoffman R (1980) Embryonic-fetal erythroid characteristics of a human leukemic cell line. Proc Natl Acad Sci USA 77: 3509-3513.
Berendji-Grun D, Kolb-Bachofen V, and Kroncke KD (2001) Nitric oxide inhibits endothelial IL-1[beta]-induced ICAM-1 gene expression at the transcriptional level decreasing Sp1 and AP-1 activity. Mol Med 7: 748-754.[Medline]
Bergeron M, Ferriero DM, Vreman HJ, Stevenson DK, and Sharp FR (1997) Hypoxia-ischemia, but not hypoxia alone, induces the expression of heme oxygenase-1 (HSP32) in newborn rat brain. J Cereb Blood Flow Metab 17: 647-658.[CrossRef][Medline]
Beri R and Chandra R (1993) Chemistry and biology of heme. Effect of metal salts, organometals and metalloporphyrins on heme synthesis and catabolism, with special reference to clinical implications and interactions with cytochrome P-450. Drug Metab Rev 25: 49-152.[Medline]
Berk PD, Blaschke TF, Scharschmidt BF, Waggoner JG, and Berlin NI (1976) A new approach to quantitation of the various sources of bilirubin in man. J Lab Clin Med 87: 767-780.[Medline]
Bernard K, Ritzel G, and Steiner KU (1954) Uber eine biologische bedeutung der gallenfarbstoffe: bilirubin und biliverdin als antioxidantien fur das vitamin A und die essentiellen fettsauren. Helv Chim Acta 37: 306-313.[CrossRef]
Bevilacqua MP (1993) Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 11: 767-804.[CrossRef][Medline]
Bonaventura C, Taboy CH, Low PS, Stevens RD, Lafon C, and Crumbliss AL (2002) Heme redox properties of S-nitrosated hemoglobin A0 and hemoglobin S: implications for interactions of nitric oxide with normal and sickle red blood cells. J Biol Chem 277: 14557-14563.
Bottomley SS and Muller-Eberhard U (1988) Pathophysiology of heme synthesis. Semin Hematol 25: 282-302.[Medline]
Braeckman L, De Bacquer D, Delanghe J, Claeys L, and De Backer G (1999) Associations between haptoglobin polymorphism, lipids, lipoproteins and inflammatory variables. Atherosclerosis 143: 383-388.[CrossRef][Medline]
Brod SA (2000) Unregulated inflammation shortens human functional longevity. Inflamm Res 49: 561-570.[CrossRef][Medline]
Brouard S, Berberat PO, Tobiasch E, Seldon MP, Bach FH, and Soares MP (2002) Heme oxygenase-1 derived carbon monoxide requires the activation of the transcription factor NF-kB to protect endothelial cells from TNF-alpha mediated apoptosis. J Biol Chem 277: 17950-17961.
Brouard S, Otterbein LE, Anrather J, Tobiasch E, Bach FH, Choi AM, and Soares MP (2000) Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. J Exp Med 192: 1015-1026.
Brune B and Ullrich V (1987) Inhibition of platelet aggregation by carbon monoxide is mediated by activation of guanylate cyclase. Mol Pharmacol 32: 497-504.[Abstract]
Buechler C, Ritter M, Orso E, Langmann T, Klucken J, and Schmitz G (2000) Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol 67: 97-103.[Abstract]
Burnett AL, Johns DG, Kriegsfeld LJ, Klein SL, Calvin DC, Demas GE, Schramm LP, Tonegawa S, Nelson RJ, Snyder SH, et al. (1998) Ejaculatory abnormalities in mice with targeted disruption of the gene for heme oxygenase-2. Nat Med 4: 84-87.[CrossRef][Medline]
Cantoni L, Rossi C, Rizzardini M, Gadina M, and Ghezzi P (1991) Interleukin-1 and tumour necrosis factor induce hepatic haem oxygenase. Feedback regulation by glucocorticoids. Biochem J 279: 891-894.
Castellani RJ, Harris PL, Lecroisey A, Izadi-Pruneyre N, Wandersman C, Perry G, and Smith MA (2000) Evidence for a novel heme-binding protein, HasAh, in Alzheimer disease. Antioxid Redox Signal 2: 137-142.[Medline]
Chapman JT, Otterbein LE, Elias JA, and Choi AM (2001) Carbon monoxide attenuates aeroallergen-induced inflammation in mice. Am J Physiol Lung Cell Mol Physiol 281: L209-L216.
Chen JJ, Crosby JS, and London IM (1994) Regulation of heme-regulated eIF-2 alpha kinase and its expression in erythroid cells. Biochimie (Paris) 76: 761-769.[Medline]
Chen JJ and London IM (1981) Hemin enhances the differentiation of mouse 3T3 cells to adipocytes. Cell 26: 117-122.[CrossRef][Medline]
Choi AM and Alam J (1996) Heme oxygenase-1: function, regulation and implication of a novel stress-inducible protein in oxidant-induced lung injury. Am J Respir Cell Mol Biol 15: 9-19.[Abstract]
Clark JE, Foresti R, Green CJ, and Motterlini R (2000) Dynamics of haem oxygenase-1 expression and bilirubin production in cellular protection against oxidative stress. Biochem J 348: 615-619.
Coburn RF, Williams WJ, and Kahn SB (1966) Endogenous carbon monoxide production in patients with hemolytic anemia. J Clin Investig 45: 460-468.
Coburn RF, Williams WJ, White P, and Kahn SB (1967) The production of carbon monoxide from hemoglobin in vivo. J Clin Investig 46: 346-356.
Conner EM and Grisham MB (1996) Inflammation, free radicals and antioxidants. Nutrition 12: 274-277.[CrossRef][Medline]
Cosso L, Maineri EP, Traverso N, Rosatto N, Pronzato MA, Cottalasso D, Marinari UM, and Odetti P (2001) Induction of heme oxygenase 1 in liver of spontaneously diabetic rats. Free Radic Res 34: 189-191.
Cotran RS and Mayadas-Norton T (1998) Endothelial adhesion molecules in health and disease. Pathol Biol (Paris) 46: 164-170.[Medline]
Cuturi MC, Christoph F, Woo J, Iyer S, Brouard S, Heslan JM, Pignon P, Soulillou JP, and Buelow R (1999) RDP1258, a new rationally designed immunosuppressive peptide, prolongs allograft survival in rats: analysis of its mechanism of action. Mol Med 5: 820-832.[Medline]
da Silva JL, Morishita T, Escalante B, Staudinger R, Drummond G, Goligorsky MS, Lutton JD, and Abraham NG (1996) Dual role of heme oxygenase in epithelial cell injury: contrasting effects of short-term and long-term exposure to oxidant stress. J Lab Clin Med 128: 290-296.[CrossRef][Medline]
Dawson JH (1988) Probing structure-function relations in heme-containing oxygenases and peroxidases. Science (Wash DC) 240: 433-439.
De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, Shin WS, and Liao JK (1995) Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Investig 96: 60-68.
Dennery PA, Weng YH, Stevenson DK, and Yang G (2001) The biology of bilirubin production. J Perinatol 21 (Suppl 1): S17-S20.
Deramaudt BM, Braunstein S, Remy P, and Abraham NG (1998) Gene transfer of human heme oxygenase into coronary endothelial cells potentially promotes angiogenesis. J Cell Biochem 68: 121-127.[CrossRef][Medline]
Dore S, Takahashi M, Ferris CD, Zakhary R, Hester LD, Guastella D, and Snyder SH (1999) Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury. Proc Natl Acad Sci USA 96: 2445-2450.
Duckers HJ, Boehm M, True AL, Yet SF, San H, Park JL, Clinton Webb R, Lee ME, Nabel GJ, and Nabel EG (2001) Heme oxygenase-1 protects against vascular constriction and proliferation. Nat Med 7: 693-698.[CrossRef][Medline]
Durante W and Schafer AI (1998) Carbon monoxide and vascular cell function (Review). Int J Mol Med 2: 255-262.[Medline]
Eisenstein RS, Garcia-Mayol D, Pettingell W, and Munro HN (1991) Regulation of ferritin and heme oxygenase synthesis in rat fibroblasts by different forms of iron. Proc Natl Acad Sci USA 88: 688-692.
Elbirt KK, Whitmarsh AJ, Davis RJ, and Bonkovsky HL (1998) Mechanism of sodium arsenite-mediated induction of heme oxygenase-1 in hepatoma cells. Role of mitogen-activated protein kinases. J Biol Chem 273: 8922-8931.
Exner M, Schillinger M, Minar E, Mlekusch W, Schlerka G, Haumer M, Mannhalter C, and Wagner O (2001) Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with restenosis after percutaneous transluminal angioplasty. J Endovasc Ther 8: 433-440.[CrossRef][Medline]
Ferris CD, Jaffrey SR, Sawa A, Takahashi M, Brady SD, Barrow RK, Tysoe SA, Wolosker H, Baranano DE, Dore S, et al. (1999) Haem oxygenase-1 prevents cell death by regulating cellular iron. Nat Cell Biol 1: 152-157.[CrossRef][Medline]
Foresti R and Motterlini R (1999) The heme oxygenase pathway and its interaction with nitric oxide in the control of cellular homeostasis. Free Radic Res Commun 31: 459-475.[CrossRef]
Foresti R, Sarathchandra P, Clark JE, Green CJ, and Motterlini R (1999) Peroxynitrite induces haem oxygenase-1 in vascular endothelial cells: a link to apoptosis. Biochem J 339: 729-736.
Frenette PS (2002) Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr Opin Hematol 9: 101-106.[CrossRef][Medline]
Fu K, Sarras MP Jr, De Lisle RC, and Andrews GK (1997) Expression of oxidative stress-responsive genes and cytokine genes during caerulein-induced acute pancreatitis. Am J Physiol 273: G696-G705.
Fuggle SV and Koo DD (1998) Cell adhesion molecules in clinical renal transplantation. Transplantation (Baltim) 65: 763-769.[CrossRef][Medline]
Gemsa D, Woo CH, Fudenberg HH, and Schmid R (1974) Stimulation of heme oxygenase in macrophages and liver by endotoxin. J Clin Investig 53: 647-651.
Gidari AS and Levere RD (1977) Enzymatic formation and cellular regulation of heme synthesis. Semin Hematol 14: 145-168.[Medline]
Goldman DW, Breyer RJ 3rd, Yeh D, Brockner-Ryan BA, and Alayash AI (1998) Acellular hemoglobin-mediated oxidative stress toward endothelium: a role for ferryl iron. Am J Physiol 275: H1046-H1053.
Gopinathan V, Miller NJ, Milner AD, and Rice-Evans CA (1994) Bilirubin and ascorbate antioxidant activity in neonatal plasma. FEBS Lett 349: 197-200.[CrossRef][Medline]
Gourley GR (1997) Bilirubin metabolism and kernicterus. Adv Pediatr 44: 173-229.[Medline]
Granick JL and Sassa S (1978) Hemin control of heme biosynthesis in mouse Friend virus-transformed erythroleukemia cells in culture. J Biol Chem 253: 5402-5406.
Guo X, Shin VY, and Cho CH (2001) Modulation of heme oxygenase in tissue injury and its implication in protection against gastrointestinal diseases. Life Sci 69: 3113-3119.[CrossRef][Medline]
Haider A, Olszanecki R, Gryglewski R, Schwartzman ML, Lianos E, Kappas A, Nasjletti A, and Abraham NG (2002) Regulation of cyclooxygenase by the hemeheme oxygenase system in microvessel endothelial cells. J Pharmacol Exp Ther 300: 188-194.
Haller H, Dragun D, Miethke A, Park JK, Weis A, Lippoldt A, Gross V, and Luft FC (1996) Antisense oligonucleotides for ICAM-1 attenuate reperfusion injury and renal failure in the rat. Kidney Int 50: 473-480.[Medline]
Hancock WW, Buelow R, Sayegh MH, and Turka LA (1998) Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nat Med 4: 1392-1396.[CrossRef][Medline]
Hanselmann C, Mauch C, and Werner S (2001) Haem oxygenase-1: a novel player in cutaneous wound repair and psoriasis? Biochem J 353: 459-466.[CrossRef][Medline]
Harrison PM and Arosio P (1996) The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1275: 161-203.[Medline]
Hayashi S, Takamiya R, Yamaguchi T, Matsumoto K, Tojo SJ, Tamatani T, Kitajima M, Makino N, Ishimura Y, and Suematsu M (1999) Induction of heme oxygenase-1 suppresses venular leukocyte adhesion elicited by oxidative stress: role of bilirubin generated by the enzyme. Circ Res 85: 663-671.
Hebbel RP (1997) Adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest 100 (Suppl 11): S83-S86.
Hogger P and Sorg C (2001) Soluble CD163 inhibits phorbol ester-induced lymphocyte proliferation. Biochem Biophys Res Commun 288: 841-843.[CrossRef][Medline]
Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, and Williams RR (1996) Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol 16: 250-255.
Horvath I, Donnelly LE, Kiss A, Paredi P, Kharitonov SA, and Barnes PJ (1998) Raised levels of exhaled carbon monoxide are associated with an increased expression of heme oxygenase-1 in airway macrophages in asthma: a new marker of oxidative stress. Thorax 53: 668-672.
Ignarro LJ (1996) Physiology and pathophysiology of nitric oxide. Kidney Int Suppl 55: S2-S5.[CrossRef][Medline]
Immenschuh S, Hinke V, Katz N, and Kietzmann T (2000) Transcriptional induction of heme oxygenase-1 gene expression by okadaic acid in primary rat hepatocyte cultures. Mol Pharmacol 57: 610-618.
Immenschuh S, Iwahara S, Satoh H, Nell C, Katz N, and Muller-Eberhard U (1995) Expression of the mRNA of heme-binding protein 23 is coordinated with that of heme oxygenase-1 by heme and heavy metals in primary rat hepatocytes and hepatoma cells. Biochemistry 34: 13407-13411.[CrossRef][Medline]
Immenschuh S, Kietzmann T, Hinke V, Wiederhold M, Katz N, and Muller-Eberhard U (1998) The rat heme oxygenase-1 gene is transcriptionally induced via the protein kinase A signaling pathway in rat hepatocyte cultures. Mol Pharmacol 53: 483-491.
Immenschuh S, Nell C, Iwahara S, Katz N, and Muller-Eberhard U (1997) Gene regulation of HBP 23 by metalloporphyrins and protoporphyrin IX in liver and hepatocyte cultures. Biochem Biophys Res Commun 231: 667-670.[CrossRef][Medline]
Immenschuh S and Ramadori G (2000) Gene regulation of heme oxygenase-1 as a therapeutic target. Biochem Pharmacol 60: 1121-1128.[CrossRef][Medline]
Immenschuh S, Stritzke J, Iwahara S, and Ramadori G (1999) Up-regulation of heme-binding protein 23 (HBP23) gene expression by lipopolysaccharide is mediated via a nitric oxide-dependent signaling pathway in rat Kupffer cells. Hepatology 30: 118-127.[CrossRef][Medline]
Inguaggiato P, Gonzalez-Michaca L, Croatt AJ, Haggard JJ, Alam J, and Nath KA (2001) Cellular overexpression of heme oxygenase-1 up-regulates p21 and confers resistance to apoptosis. Kidney Int 60: 2181-2191.[CrossRef][Medline]
Ishii DN and Maniatis GM (1978) Haemin promotes rapid neurite outgrowth in cultured mouse neuroblastoma cells. Nature (Lond) 274: 372-374.[CrossRef][Medline]
Ishizaka N and Griendling KK (1997) Heme oxygenase-1 is regulated by angiotensin II in rat vascular smooth muscle cells. Hypertension 29: 790-795.
Jacob HS (1994) Newly recognized causes of atherosclerosis: the role of microorganisms and of vascular iron overload. J Lab Clin Med 123: 808-816.[Medline]
Jeney V, Balla J, Yachie A, Varga Z, Vercellotti GM, Eaton JW, and Balla G (2002) Pro-oxidant and cytotoxic effects of circulating heme. Blood 100: 879-887.
Johnson RA, Kozma F, and Colombari E (1999) Carbon monoxide: from toxin to endogenous modulator of cardiovascular functions. Braz J Med Biol Res 32: 1-14.[Medline]
Johnson RA, Lavesa M, Askari B, Abraham NG, and Nasjletti A (1995) A heme oxygenase product, presumably carbon monoxide, mediates a vasodepressor function in rats. Hypertension 25: 166-169.
Jordi-Racine AL, Alvarez E, and Reichen J (1988) The effect of hypoxia on hepatic cytochromes and heme turnover in rats in vivo. Experientia (Basel) 44: 343-345.[CrossRef][Medline]
Kappas A and Drummond GS (1986) Control of heme metabolism with synthetic metalloporphyrins. J Clin Investig 77: 335-339.
Kappas A, Drummond GS, and Galbraith RA (1993) Prolonged clinical use of a heme oxygenase inhibitor: hematological evidence for an inducible but reversible iron-deficiency state. Pediatrics 91: 537-539.
Kappas A, Drummond GS, Henschke C, and Valaes T (1995a) Direct comparison of Sn-mesoporphyrin, an inhibitor of bilirubin production and phototherapy in controlling hyperbilirubinemia in term and near-term newborns. Pediatrics 95: 468-474.
Kappas A, Drummond GS, Munson DP, and Marshall JR (2001) Sn-Mesoporphyrin interdiction of severe hyperbilirubinemia in Jehovah's Witness newborns as an alternative to exchange transfusion. Pediatrics 108: 1374-1377.
Kappas A, Sassa S, Galbraith RA, and Nordmann Y (1995b) The porphyrias, in The Metabolic and Molecular Basis of Inherited Diseases (Scriver CR, Beaudet A, Sly WS, and Valle D, eds) pp 2116-2127, McGraw-Hill Companies, New York.
Katori M, Buelow R, Ke B, Ma J, Coito AJ, Iyer S, Southard D, Busuttil RW, and Kupiec-Weglinski JW (2002) Heme oxygenase-1 overexpression protects rat hearts from cold ischemia/reperfusion injury via an antiapoptotic pathway. Transplantation (Baltim) 73: 287-292.[CrossRef][Medline]
Kawashima A, Oda Y, Yachie A, Koizumi S, and Nakanishi I (2002) Heme oxygenase-1 deficiency: the first autopsy case. Hum Pathol 33: 125-130.[CrossRef][Medline]
Ke B, Shen XD, Zhai Y, Gao F, Busuttil RW, Volk HD, and Kupiec-Weglinski JW (2002) Heme oxygenase 1 mediates the immunomodulatory and antiapoptotic effects of interleukin 13 gene therapy in vivo and in vitro. Hum Gene Ther 13: 1845-1857.[CrossRef][Medline]
Keyse SM and Tyrrell RM (1989) Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide and sodium arsenite. Proc Natl Acad Sci USA 86: 99-103.
Koizumi T, Negishi M, and Ichikawa A (1992) Induction of heme oxygenase by delta 12-prostaglandin J2 in porcine aortic endothelial cells. Prostaglandins 43: 121-131.[CrossRef][Medline]
Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, and Moestrup SK (2001) Identification of the haemoglobin scavenger receptor. Nature (Lond) 409: 198-201.[CrossRef][Medline]
Lane JL (1998) Blood ties. The Sciences 9 -10: 24-29.
Langlois MR and Delanghe JR (1996) Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 42: 1589-1600
Laniado-Schwartzman M, Abraham NG, Conners M, Dunn MW, Levere RD, and Kappas A (1997) Heme oxygenase induction with attenuation of experimentally induced corneal inflammation. Biochem Pharmacol 53: 1069-1075.[CrossRef][Medline]
Lathrop JT and Timko MP (1993) Regulation by heme of mitochondrial protein transport through a conserved amino acid motif. Science (Wash DC) 259: 522-525.
Lautier D, Luscher P, and Tyrrell RM (1992) Endogenous glutathione levels modulate both constitutive and UVA radiation/hydrogen peroxide inducible expression of the human heme oxygenase gene. Carcinogenesis 13: 227-232.
Lavrovsky Y, Schwartzman ML, Levere RD, Kappas A, and Abraham NG (1994) Identification of binding sites for transcription factors NF-kappa B and AP-2 in the promoter region of the human heme oxygenase 1 gene. Proc Natl Acad Sci USA 91: 5987-5991.
Lavrovsky Y, Song CS, Chatterjee B, and Roy AK (2000) Age-dependent increase of heme oxygenase-1 gene expression in the liver mediated by NFkappaB. Mech Ageing Dev 114: 49-60.[CrossRef][Medline]
Lee HC, Hon T, and Zhang L (2002) The molecular chaperone Hsp90 mediates heme activation of the yeast transcriptional activator Hap1. J Biol Chem 277: 7430-7437.
Lee PJ, Alam J, Sylvester SL, Inamdar N, Otterbein L, and Choi AM (1996a) Regulation of heme oxygenase-1 expression in vivo and in vitro in hyperoxic lung injury. Am J Respir Cell Mol Biol 14: 556-568.[Abstract]
Lee PJ, Alam J, Wiegand GW, and Choi AM (1996b) Overexpression of heme oxygenase-1 in human pulmonary epithelial cells results in cell growth arrest and increased resistance to hyperoxia. Proc Natl Acad Sci USA 93: 10393-10398.
Lee TS and Chau LY (2002) Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat Med 8: 240-246.[CrossRef][Medline]
Letarte PB, Lieberman K, Nagatani K, Haworth RA, Odell GB, and Duff TA (1993) Hemin: levels in experimental subarachnoid hematoma and effects on dissociated vascular smooth-muscle cells. J Neurosurg 79: 252-255.[Medline]
Levere RD, Staudinger R, Loewy G, Kappas A, Shibahara S, and Abraham NG (1993) Elevated levels of heme oxygenase-1 activity and mRNA in peripheral blood adherent cells of acquired immunodeficiency syndrome patients. Am J Hematol 43: 19-23.[Medline]
Li L, Hamilton RF Jr, and Holian A (2000) Protection against ozone-induced pulmonary inflammation and cell death by endotoxin pretreatment in mice: role of HO-1. Inhal Toxicol 12: 1225-1238.[CrossRef][Medline]
Li X and David Clark J (2000) Chronic morphine exposure and the expression of heme oxygenase type 2. Brain Res Mol Brain Res 75: 179-184.[Medline]
Liang M, Croatt AJ, and Nath KA (2000) Mechanisms underlying induction of heme oxygenase-1 by nitric oxide in renal tubular epithelial cells. Am J Physiol Renal Physiol 279: F728-F735.
Liu N, Wang X, McCoubrey WK, and Maines MD (2000) Developmentally regulated expression of two transcripts for heme oxygenase-2 with a first exon unique to rat testis: control by corticosterone of the oxygenase protein expression. Gene (Amst) 241: 175-183.[CrossRef][Medline]
London IM, West K, Shemin D, and Rittenberg D (1950) On the origin of bile pigment in normal man. J Biol Chem 184: 351-358.
Maestrelli P, El Messlemani AH, De Fina O, Nowicki Y, Saetta M, Mapp C, and Fabbri LM (2001) Increased expression of heme oxygenase (HO)-1 in alveolar spaces and HO-2 in alveolar walls of smokers. Am J Respir Crit Care Med 164: 1508-1513.
Magee CC, Azuma H, Knoflach A, Denton MD, Chandraker A, Iyer S, Buelow R, and Sayegh M (1999) In vitro and in vivo immunomodulatory effects of RDP1258, a novel synthetic peptide. J Am Soc Nephrol 10: 1997-2005.
Maines MD (1992) Heme Oxygenase: Clinical Applications and Functions, CRC Press LLC, Boca Raton, FL.
Maines MD (1997) The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 37: 517-554.[CrossRef][Medline]
Maines MD (2000) The heme oxygenase system and its functions in the brain. Cell Mol Biol (Noisy-Le-Grand) 46: 573-585.[Medline]
Maines MD and Abrahamsson PA (1996) Expression of heme oxygenase-1 (HSP32) in human prostate: normal, hyperplastic and tumor tissue distribution. Urology 47: 727-733.[CrossRef][Medline]
Maines MD and Kappas A (1974) Cobalt induction of hepatic heme oxygenase; with evidence that cytochrome P-450 is not essential for this enzyme activity. Proc Natl Acad Sci USA 71: 4293-4297.
Maines MD and Kappas A (1975) Cobalt stimulation of heme degradation in the liver. Dissociation of microsomal oxidation of heme from cytochrome P-450. J Biol Chem 250: 4171-4177.
Maines MD, Mayer RD, Ewing JF, and McCoubrey WK Jr(1993) Induction of kidney heme oxygenase-1 (HSP32) mRNA and protein by ischemia/reperfusion: possible role of heme as both promotor of tissue damage and regulator of HSP32. J Pharmacol Exp Ther 264: 457-462.
Maines MD and Panahian N (2001) The heme oxygenase system and cellular defense mechanisms. Do HO-1 and HO-2 have different functions? Adv Exp Med Biol 502: 249-272.[Medline]
Maines MD and Trakshel GM (1992) Differential regulation of heme oxygenase isozymes by Sn-and Zn-protoporphyrins: possible relevance to suppression of hyperbilirubinemia. Biochim Biophys Acta 1131: 166-174.[Medline]
Maines MD, Trakshel GM, and Kutty RK (1986) Characterization of two constitutive forms of rat liver microsomal heme oxygenase. Only one molecular species of the enzyme is inducible. J Biol Chem 261: 411-419.
Maniatis GM, Ramirez F, Cann A, Marks PA, and Bank A (1976) Translation and stability of human globin mRNA in Xenopus oocytes. J Clin Investig 58: 1419-1427.
Marks GS (1994) Heme oxygenase: the physiological role of one of its metabolites, carbon monoxide and interactions with zinc protoporphyrin, cobalt protoporphyrin and other metalloporphyrins. Cell Mol Biol (Noisy-Le-Grand) 40: 863-870.
Marks GS, Brien JF, Nakatsu K, and McLaughlin BE (1991) Does carbon monoxide have a physiological function? Trends Pharmacol Sci 12: 185-188.[CrossRef][Medline]
Martinez JC, Garcia HO, Otheguy LE, Drummond GS, and Kappas A (2001) Treatment of hyperbilirubinemia pharmacologic approach SnMP(tin-mesoporphyrin). J Perinatol 21 (Suppl 1): S101-S103; discussion S104 -S107.
Mautes AE, Kim DH, Sharp FR, Panter S, Sato M, Maida N, Bergeron M, Guenther K, and Noble LJ (1998) Induction of heme oxygenase-1 (HO-1) in the contused spinal cord of the rat. Brain Res 795: 17-24.[CrossRef][Medline]
McCoubrey WK Jr, Huang TJ, and Maines MD (1997) Isolation and characterization of a cDNA from the rat brain that encodes hemoprotein heme oxygenase-3. Eur J Biochem 247: 725-732.[Medline]
McDonagh AF and Lightner DA (1985) 'Like a shrivelled blood orange'— bilirubin, jaundice and phototherapy. Pediatrics 75: 443-455.
Megyesi J, Safirstein RL, and Price PM (1998) Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. J Clin Investig 101: 777-782.[Medline]
Melo LG, Agrawal R, Zhang L, Rezvani M, Mangi AA, Ehsan A, Griese DP, Dell'Acqua G, Mann MJ, Oyama J, et al. (2002) Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation 105: 602-607.
Menger MD and Vollmar B (1996) Adhesion molecules as determinants of disease: from molecular biology to surgical research. Br J Surg 83: 588-601.[Medline]
Minamino T, Christou H, Hsieh CM, Liu Y, Dhawan V, Abraham NG, Perrella MA, Mitsialis SA, and Kourembanas S (2001) Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia. Proc Natl Acad Sci USA 98: 8798-8803
Montellano PR (2000) The mechanism of heme oxygenase. Curr Opin Chem Biol 4: 221-227.[CrossRef][Medline]
Moore CM, Ehlayel M, Leiva LE, and Sorensen RU (1996) New concepts in the immunology of sickle cell disease. Ann Allergy Asthma Immunol 76: 385-400; quiz 400-403.[Medline]
Moore K (1999) Cell biology of chronic wounds: the role of inflammation. J Wound Care 8: 345-348.[Medline]
Morita T and Kourembanas S (1995) Endothelial cell expression of vasoconstrictors and growth factors is regulated by smooth muscle cell-derived carbon monoxide. J Clin Investig 96: 2676-2682.
Morse D and Choi AM (2002) Heme oxygenase-1. The "emerging molecule" has arrived. Am J Respir Cell Mol Biol 27: 8-16.
Mosley K, Wembridge DE, Cattell V, and Cook HT (1998) Heme oxygenase is induced in nephrotoxic nephritis and hemin, a stimulator of heme oxygenase synthesis, ameliorates disease. Kidney Int 53: 672-678.[CrossRef][Medline]
Motohashi H, Shavit JA, Igarashi K, Yamamoto M, and Engel JD (1997) The world according to Maf. Nucleic Acids Res 25: 2953-2959.
Muller-Eberhard U and Fraig M (1993) Bioactivity of heme and its containment. Am J Hematol 42: 59-62.[Medline]
Muller-Eberhard U, Javid J, Liem HH, Hanstein A, and Hanna M (1968) Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases. Blood 32: 811-815.
Nath KA (1999) Heme oxygenase-1: a redoubtable response that limits reperfusion injury in the transplanted adipose liver. J Clin Investig 104: 1485-1486.[Medline]
Nath KA, Balla G, Vercellotti GM, Balla J, Jacob HS, Levitt MD, and Rosenberg ME (1992) Induction of heme oxygenase is a rapid, protective response in rhabdomyolysis in the rat. J Clin Investig 90: 267-270.
Nath KA, Balla J, Croatt AJ, and Vercellotti GM (1995) Heme protein-mediated renal injury: a protective role for 21-aminosteroids in vitro and in vivo. Kidney Int 47: 592-602.[Medline]
Nath KA, Grande JP, Croatt AJ, Likely S, Hebbel RP, and Enright H (1998) Intracellular targets in heme protein-induced renal injury. Kidney Int 53: 100-111.[CrossRef][Medline]
Nath KA, Grande JP, Haggard JJ, Croatt AJ, Katusic ZS, Solovey A, and Hebbel RP (2001a) Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. Am J Pathol 158: 893-903.
Nath KA, Haggard JJ, Croatt AJ, Grande JP, Poss KD, and Alam J (2000) The indispensability of heme oxygenase-1 in protecting against acute heme protein-induced toxicity in vivo. Am J Pathol 156: 1527-1535.
Nath KA, Vercellotti GM, Grande JP, Miyoshi H, Paya CV, Manivel JC, Haggard JJ, Croatt AJ, Payne WD, and Alam J (2001b) Heme protein-induced chronic renal inflammation: suppressive effect of induced heme oxygenase-1. Kidney Int 59: 106-117.[CrossRef][Medline]
Oberyszyn TM, Robertson FM, Tober KL, Ross MS, Parrett ML, Wilgus TA, Iyer S, Woo J, and Buelow R (2001) Inhibition of cutaneous UV light-induced tumor necrosis factor-alpha protein production by Allotrap 1258, a novel immunomodulatory peptide. Photochem Photobiol 73: 184-190.[CrossRef][Medline]
Ogawa K, Sun J, Taketani S, Nakajima O, Nishitani C, Sassa S, Hayashi N, Yamamoto M, Shibahara S, Fujita H, et al. (2001) Heme mediates derepression of Maf recognition element through direct binding to transcription repressor Bach1. EMBO (Eur Mol Biol Organ) J 20: 2835-2843.[CrossRef][Medline]
Oguro T, Hayashi M, Nakajo S, Numazawa S, and Yoshida T (1998) The expression of heme oxygenase-1 gene responded to oxidative stress produced by phorone, a glutathione depletor, in the rat liver; the relevance to activation of c-jun n-terminal kinase. J Pharmacol Exp Ther 287: 773-778.
Ostrow JD, Jandl JH, and Schmid R (1962) The formation of bilirubin from hemoglobin in vivo. J Clin Investig 41: 1628-1637.
Otterbein L, Chin BY, Otterbein SL, Lowe VC, Fessler HE, and Choi AM (1997) Mechanism of hemoglobin-induced protection against endotoxemia in rats: a ferritin-independent pathway. Am J Physiol 272: L268-L275.
Otterbein L, Sylvester SL, and Choi AM (1995) Hemoglobin provides protection against lethal endotoxemia in rats: the role of heme oxygenase-1. Am J Respir Cell Mol Biol 13: 595-601.[Abstract]
Otterbein LE, Bach FH, Alam J, Soares M, Tao Lu H, Wysk M, Davis RJ, Flavell RA, and Choi AM (2000) Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med 6: 422-428.[CrossRef][Medline]
Otterbein LE and Choi AM (2000) Heme oxygenase: colors of defense against cellular stress. Am J Physiol Lung Cell Mol Physiol 279: L1029-L1037.
Otterbein LE, Kolls JK, Mantell LL, Cook JL, Alam J, and Choi AM (1999a) Exogenous administration of heme oxygenase-1 by gene transfer provides protection against hyperoxia-induced lung injury. J Clin Investig 103: 1047-1054.[Medline]
Otterbein LE, Mantell LL, and Choi AM (1999b) Carbon monoxide provides protection against hyperoxic lung injury. Am J Physiol 276: L688-L694.
Panahian N, Yoshiura M, and Maines MD (1999) Overexpression of heme oxgenase-1 is neuroprotective in a model of permanent middle cerebral artery occlusion in transgenic mice. J Neurochem 72: 1187-1203[Medline]
Partanen S, Pasanen A, Juvonen E, Tenhunen R, and Ruutu T (1988) Erythroid colony formation and effect of hemin in vitro in hereditary sideroblastic anemias. Exp Hematol (Copenh) 16: 313-315.[Medline]
Pellacani A, Wiesel P, Sharma A, Foster LC, Huggins GS, Yet SF, and Perrella MA (1998) Induction of heme oxygenase-1 during endotoxemia is downregulated by transforming growth factor-beta1. Circ Res 83: 396-403.
Petrache I, Otterbein LE, Alam J, Wiegand GW, and Choi AM (2000) Heme oxgenase-1 inhibits TNF-alpha-induced apoptosis in cultured fibroblasts. Am J Physiol Lung Cell Mol Physiol 278: L312-L319.
Pfeifer K, Arcangioli B, and Guarente L (1987) Yeast HAP1 activator competes with the factor RC2 for binding to the upstream activation site UAS1 of the CYC1 gene. Cell 49: 9-18.[CrossRef][Medline]
Pfeifer K, Kim KS, Kogan S, and Guarente L (1989) Functional dissection and sequence of yeast HAP1 activator. Cell 56: 291-301.[CrossRef][Medline]
Pileggi A, Molano RD, Berney T, Cattan P, Vizzardelli C, Oliver R, Fraker C, Ricordi C, Pastori RL, Bach FH, et al. (2001) Heme oxygenase-1 induction in islet cells results in protection from apoptosis and improved in vivo function after transplantation. Diabetes 50: 1983-1991.
Platt JL and Nath KA (1998) Heme oxygenase: protective gene or Trojan horse. Nat Med 4: 1364-1365.[CrossRef][Medline]
Polte T, Abate A, Dennery PA, and Schroder H (2000) Heme oxygenase-1 is a cGMP-inducible endothelial protein and mediates the cytoprotective action of nitric oxide. Arterioscler Thromb Vasc Biol 20: 1209-1215.
Polyak K, Waldman T, He TC, Kinzler KW, and Vogelstein B (1996) Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 10: 1945-1952.
Ponka P (1999) Cell biology of heme. Am J Med Sci 318: 241-256.[CrossRef][Medline]
Poss KD and Tonegawa S (1997a) Heme oxygenase 1 is required for mammalian iron reutilization. Proc Natl Acad Sci USA 94: 10919-10924.
Poss KD and Tonegawa S (1997b) Reduced stress defense in heme oxygenase 1-de-ficient cells. Proc Natl Acad Sci USA 94: 10925-10930.
Quan S, Yang L, Abraham NG, and Kappas A (2001) Regulation of human heme oxygenase in endothelial cells by using sense and antisense retroviral constructs. Proc Natl Acad Sci USA 98: 12203-12208.
Ribeiro MM, Klein D, Pileggi A, Damaris Molano R, Fraker C, Ricordi C, Inverardi L, and Pastori RL (2003) Heme oxygenase-1 fused to a TAT peptide transduces and protects pancreatic beta-cells. Biochem Biophys Res Commun 305: 876-881.[CrossRef][Medline]
Robbins SL, Cotran RS, Kumar V, Collins T, and Albert DM (1999) Pathological Basis of Disease, W. B. Saunders Company, Philadelphia, PA.
Roguin A, Hochberg I, Nikolsky E, Markiewicz W, Meisel SR, Hir J, Grenadier E, Beyar R, and Levy AP (2001) Haptoglobin phenotype as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 87: 330-332, A9.[CrossRef][Medline]
Rucker M, Schafer T, Roesken F, Spitzer WJ, Bauer M, and Menger MD (2001) Reduction of inflammatory response in composite flap transfer by local stress conditioning-induced heat-shock protein 32. Surgery 129: 292-301.[CrossRef][Medline]
Rutherford TR and Harrison PR (1979) Globin synthesis and erythroid differentiation in a Friend cell variant deficient in heme synthesis. Proc Natl Acad Sci USA 76: 5660-5664.
Ryter SW and Tyrrell RM (2000) The heme synthesis and degradation pathways: role in oxidant sensitivity. Heme oxygenase has both pro-and antioxidant properties. Free Radic Biol Med 28: 289-309.[CrossRef][Medline]
Sabaawy HE, Zhang F, Nguyen X, ElHosseiny A, Nasjletti A, Schwartzman M, Dennery P, Kappas A, and Abraham NG (2001) Human heme oxygenase-1 gene transfer lowers blood pressure and promotes growth in spontaneously hypertensive rats. Hypertension 38: 210-215.
Sarady JK, Otterbein SL, Liu F, Otterbein LE, and Choi AM (2002) Carbon monoxide modulates endotoxin-induced production of granulocyte macrophage colony-stimulating factor in macrophages. Am J Respir Cell Mol Biol 27: 739-745.
Sardana MK, Drummond GS, Sassa S, and Kappas A (1981) The potent heme oxygenase inducing action of arsenic and parasiticidal arsenicals. Pharmacology 23: 247-253.[CrossRef][Medline]
Sassa S (1976) Sequential induction of heme pathway enzymes during erythroid differentiation of mouse Friend leukemia virus-infected cells. J Exp Med 143: 305-315.
Sassa S and Nagai T (1996) The role of heme in gene expression. Int J Hematol 63: 167-178.[CrossRef][Medline]
Sato K, Balla J, Otterbein L, Smith RN, Brouard S, Lin Y, Csizmadia E, Sevigny J, Robson SC, Vercellotti G, et al. (2001) Carbon monoxide generated by heme oxygenase-1 suppresses the rejection of mouse-to-rat cardiac transplants. J Immunol 166: 4185-4194.
Seed MP and Willoughby DA (1997) COX-2, HO NO! Cyclooxygenase-2, heme oxygenase and nitric oxide synthase: their role and interactions in inflammation. BIRAs Symposium, Saint Bartholomew's Hospital, London, 1996 April 26. Inflamm Res 46: 279-281.[CrossRef][Medline]
Shemin D (1970) On the synthesis of heme. Naturwissenschaften 57: 185-190.[CrossRef][Medline]
Shemin D (1989) An illustration of the use of isotopes: the biosynthesis of porphyrins. Bioessays 10: 30-35.[CrossRef][Medline]
Shemin D and Rittenberg D (1946) The life span of the red blood cell. J Biol Chem 166: 627-636.
Shemin D, Russell CS, and Abramsky T (1953) Aminolevulinic acid, its role in the synthesis of porphyrins and purines. J Am Chem Soc 75: 4873-4875.[CrossRef]
Shemin D and Wittenberg J (1951) The mechanism of porphyrin formation: the role of the tricarboxylic acid cycle. J Biol Chem 192: 315-334.
Shibahara S (1994) Heme oxygenase-Regulation and physiological implication in heme metabolism, in Regulation of Heme Protein Synthesis (Fujita H ed) pp 103-116, AlphaMed Press, Dayton, OH. Shibahara S, Muller RM, and Taguchi H (1987) Transcriptional control of rat heme oxygenase by heat shock. J Biol Chem 262: 12889-12892.
Shiu YT, Udden MM, and McIntire LV (2000) Perfusion with sickle erythrocytes up-regulates ICAM-1 and VCAM-1 gene expression in cultured human endothelial cells. Blood 95: 3232-3241.
Shono T, Ono M, Izumi H, Jimi SI, Matsushima K, Okamoto T, Kohno K, and Kuwano M (1996) Involvement of the transcription factor NF-kappaB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol Cell Biol 16: 4231-4239.[Abstract]
Simoni J, Simoni G, Lox CD, Prien SD, Tran R, and Shires GT (1997) Expression of adhesion molecules and von Willebrand factor in human coronary artery endothelial cells incubated with differently modified hemoglobin solutions. Artif Cells Blood Substit Immobil Biotechnol 25: 211-225.[Medline]
Siow RC, Sato H, and Mann GE (1999) Heme oxygenase-carbon monoxide signalling pathway in atherosclerosis: anti-atherogenic actions of bilirubin and carbon mon-oxide? Cardiovasc Res 41: 385-394.
Sjoestrand T (1949a) Endogenous formation of carbon monoxide in man under normal and pathological conditions. J Clin Lab Investig 1: 201-208.
Sjoestrand T (1949b) Endogenous formation of carbon monoxide in man. Nature (Lond) 164: 580-581.[CrossRef][Medline]
Smith MA, Kutty RK, Richey PL, Yan SD, Stern D, Chader GJ, Wiggert B, Petersen RB, and Perry G (1994) Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol 145: 42-47.[Abstract]
Snyder SH and Baranano DE (2001) Heme oxygenase: a font of multiple messengers. Neuropsychopharmacology 25: 294-298.[CrossRef][Medline]
Soares MP, Lin Y, Anrather J, Csizmadia E, Takigami K, Sato K, Grey ST, Colvin RB, Choi AM, Poss KD, et al. (1998) Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nat Med 4: 1073-1077.[CrossRef][Medline]
Solovey AA, Solovey AN, Harkness J, and Hebbel RP (2001) Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood 97: 1937-1941.
Song R, Ning W, Liu F, Ameredes BT, Calhoun WJ, Otterbein LE, and Choi AM (2003) Regulation of IL-1beta -induced GM-CSF production in human airway smooth muscle cells by carbon monoxide. Am J Physiol Lung Cell Mol Physiol 284: L50-L56.
Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, and Ames BN (1987) Bilirubin is an antioxidant of possible physiological importance. Science (Wash DC) 235: 1043-1046.
Suttner DM and Dennery PA (1999) Reversal of HO-1 related cytoprotection with increased expression is due to reactive iron. FASEB J 13: 1800-1809.
Swenson GR, Patino MM, Beck MM, Gaffield L, and Walden WE (1991) Characteristics of the interaction of the ferritin repressor protein with the iron-responsive element. Biol Met 4: 48-55.[CrossRef][Medline]
Takahashi K, Nakayama M, Takeda K, Fujia H, and Shibahara S (1999) Suppression of heme oxygenase-1 mRNA expression by interferon-gamma in human glioblastoma cells. J Neurochem 72: 2356-2361.[CrossRef][Medline]
Takahashi M, Dore S, Ferris CD, Tomita T, Sawa A, Wolosker H, Borchelt DR, Iwatsubo T, Kim SH, Thinakaran G, et al. (2000) Amyloid precursor proteins inhibit heme oxygenase activity and augment neurotoxicity in Alzheimer's disease. Neuron 28: 461-473.[CrossRef][Medline]
Takahashi M and Snyder SH (2000) Interaction of amyloid precursor proteins and heme oxygenase. Alzheimer Dis Assoc Disord 14 (Suppl 1): S67-S71.
Tamion F, Richard V, Bonmarchand G, Leroy J, Lebreton JP, and Thuillez C (2001) Induction of heme-oxygenase-1 prevents the systemic responses to hemorrhagic shock. Am J Respir Crit Care Med 164: 1933-1938.
Tenhunen R, Marver HS, and Schmid R (1968) The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci USA 61: 748-755.
Tenhunen R, Marver HS, and Schmid R (1969) Microsomal heme oxygenase. Characterization of the enzyme. J Biol Chem 244: 6388-6394.
Tenhunen R, Marver HS, and Schmid R (1970) The enzymatic catabolism of hemoglobin: stimulation of microsomal heme oxygenase by hemin. J Lab Clin Med 75: 410-421.[Medline]
Tephly TR, Hasegawa E, and Baron J (1971) Effect of drugs on heme synthesis in the liver. Metabolism 20: 200-214.[CrossRef][Medline]
Terry CM, Clikeman JA, Hoidal JR, and Callahan KS (1999) TNF-alpha and IL-1alpha induce heme oxygenase-1 via protein kinase C, Ca2+ and phospholipase A2 in endothelial cells. Am J Physiol 276: H1493-H501.
Terry MJ, Linley PJ, and Kohchi T (2002) Making light of it: the role of plant haem oxygenases in phytochrome chromophore synthesis. Biochem Soc Trans 30: 604-609.[CrossRef][Medline]
Tetsuka T, Daphna-Iken D, Srivastava SK, and Morrison AR (1995) Regulation of heme oxygenase mRNA in mesangial cells: prostaglandin E2 negatively modulates interleukin-1-induced heme oxygenase-1 mRNA. Biochem Biophys Res Commun 212: 617-623.[CrossRef][Medline]
Togane Y, Morita T, Suematsu M, Ishimura Y, Yamazaki JI, and Katayama S (2000) Protective roles of endogenous carbon monoxide in neointimal development elicited by arterial injury. Am J Physiol Heart Circ Physiol 278: H623-H632.
Torti FM and Torti SV (2002) Regulation of ferritin genes and protein. Blood 99: 3505-3516.
Tsuji A, Wang J, Stenzel KH, and Novogrodsky A (1993) Immune stimulatory and anti-tumour properties of haemin. Clin Exp Immunol 93: 308-312.[Medline]
Tulis DA, Durante W, Liu X, Evans AJ, Peyton KJ, and Schafer AI (2001) Adenovirus-mediated heme oxygenase-1 gene delivery inhibits injury-induced vascular neointima formation. Circulation 104: 2710-2715.
Tullius SG, Nieminen-Kelha M, Buelow R, Reutzel-Selke A, Martins PN, Pratschke J, Bachmann U, Lehmann M, Southard D, Iyer S, et al. (2002) Inhibition of ischemia/reperfusion injury and chronic graft deterioration by a single-donor treatment with cobalt-protoporphyrin for the induction of heme oxygenase-1. Transplantation 74: 591-598.[Medline]
Tullius SG, Nieminen-Kelha M, Bachmann U, Reutzel-Selke A, Jonas S, Pratschke J, Bechstein WO, Reinke P, Buelow R, Neuhaus P, et al. (2001) Induction of heme-oxygenase-1 prevents ischemia/reperfusion injury and improves long-term graft outcome in rat renal allografts. Transplant Proc 33: 1286-1287.[CrossRef][Medline]
Tyrrell R (1999) Redox regulation and oxidant activation of heme oxygenase-1. Free Radic Res 31: 335-340.[CrossRef][Medline]
Vachharajani TJ, Work J, Issekutz AC, and Granger DN (2000) Heme oxygenase modulates selectin expression in different regional vascular beds. Am J Physiol Heart Circ Physiol 278: H1613-H1617.
van Der Vliet A, Eiserich JP, and Cross CE (2000) Nitric oxide: a pro-inflammatory mediator in lung disease? Respir Res 1: 67-72.[CrossRef][Medline]
Van Langendonckt A, Casanas-Roux F, Dolmans MM, and Donnez J (2002) Potential involvement of hemoglobin and heme in the pathogenesis of peritoneal endometriosis. Fertil Steril 77: 561-570.[CrossRef][Medline]
Vercellotti GM, Balla G, Balla J, Nath K, Eaton JW, and Jacob HS (1994) Heme and the vasculature: an oxidative hazard that induces antioxidant defenses in the endothelium. Artif Cells Blood Substit Immobil Biotechnol 22: 207-213.[Medline]
Verger C, Sassa S, and Kappas A (1983) Growth-promoting effects of iron-and cobalt-protoporphyrins on cultured embryonic cells. J Cell Physiol 116: 135-141.[CrossRef][Medline]
Vile GF, Basu-Modak S, Waltner C, and Tyrrell RM (1994) Heme oxygenase 1 mediates an adaptive response to oxidative stress in human skin fibroblasts. Proc Natl Acad Sci USA 91: 2607-2610.
Virchow R (1847) Die pathologischen pigments. Arch Pathol Anat 1: 379-486.[CrossRef]
Vogt BA, Shanley TP, Croatt A, Alam J, Johnson KJ, and Nath KA (1996) Glomerular inflammation induces resistance to tubular injury in the rat. A novel form of acquired, heme oxygenase-dependent resistance to renal injury. J Clin Investig 98: 2139-2145.[Medline]
Volin L, Ruutu T, Knuutila S, and Tenhunen R (1988) Heme arginate treatment for myelodysplastic syndromes. Leuk Res 12: 423-431.[CrossRef][Medline]
Wagener FADTG, Abraham NG, van Kooyk Y, de Witte T, and Figdor CG (2001a) Heme-induced cell adhesion in the pathogenesis of sickle-cell disease and inflammation. Trends Pharmacol Sci 22: 52-54.[CrossRef][Medline]
Wagener FADTG, da Silva JL, Farley T, de Witte T, Kappas A, and Abraham NG (1999) Differential effects of heme oxygenase isoforms on heme mediated endothelial ICAM-1 expression. J Pharmacol Exp Ther 291: 416-423.
Wagener FADTG, Eggert A, Boerman OC, Oyen WJ, Verhofstad A, Abraham NG, Adema G, van Kooyk Y, de Witte T, and Figdor CG (2001b) Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. Blood 98: 1802-1811.
Wagener FADTG, Feldman E, de Witte T, and Abraham NG (1997) Heme induces the expression of adhesion molecules ICAM-1, VCAM-1 and E selectin in vascular endothelial cells. Proc Soc Exp Biol Med 216: 456-463.[CrossRef][Medline]
Wagener FADTG, Van Beurden HE, Von den Hoff JW, Adema GJ, and Figdor CG (2003a) The heme-heme oxygenase system: a molecular switch in wound healing? Blood 102: 521-528.
Wagener FADTG, van Horssen J, Kuiper JWP, Den Brok MHMGM, De Waal RMW, Verbeek MM, Adema GJ, and Figdor CG (2003b). The heme-heme oxygenase system in Alzheimer's disease Blood, in press.
Wagner CT, Durante W, Christodoulides N, Hellums JD, and Schafer AI (1997) Hemodynamic forces induce the expression of heme oxygenase in cultured vascular smooth muscle cells. J Clin Investig 100: 589-596.[Medline]
Watson CJ (1965) Reminiscences of Hans Fischer and his laboratory. Perspect Biol Med 8: 419-435.[Medline]
Willis D (1995) Expression and modulatory effects of heme oxygenase in acute inflammation in the rat. Inflamm Res 44 (Suppl 2): S218-S220.
Willis D, Moore AR, Frederick R, and Willoughby DA (1996) Heme oxygenase: a novel target for the modulation of the inflammatory response. Nat Med 2: 87-90.[CrossRef][Medline]
Willis D, Moore AR, and Willoughby DA (2000) Heme oxygenase isoform expression in cellular and antibody-mediated models of acute inflammation in the rat. J Pathol 190: 627-634.[CrossRef][Medline]
Willis D, Tomlinson A, Frederick R, Paul-Clark MJ, and Willoughby DA (1995) Modulation of heme oxygenase activity in rat brain and spleen by inhibitors and donors of nitric oxide. Biochem Biophys Res Commun 214: 1152-1156.[CrossRef][Medline]
Willoughby DA, Moore AR, Colville-Nash PR, and Gilroy D (2000) Resolution of inflammation. Int J Immunopharmacol 22: 1131-1135.[CrossRef][Medline]
Wise CD and Drabkin DL (1964) Degradation of haemoglobin and hemin to biliverdin by a new cell-free system obtained from the hemophagous organ of dog placenta. Fed Proc 23: 323.
Wolin MS, Davidson CA, Kaminski PM, Fayngersh RP, and Mohazzab HK (1998) Oxidant-nitric oxide signalling mechanisms in vascular tissue. Biochemistry (Mosc) 63: 810-816.[Medline]
Wuyts B, Delanghe JR, Kasvosve I, Langlois MR, De Buyzere ML, and Janssens J (2000) A new method for fast haptoglobin phenotyping and hemoglobin binding capacity calculation based on capillary zone electrophoresis. Clin Chem Lab Med 38: 715-720.[CrossRef][Medline]
Yachie A, Niida Y, Wada T, Igarashi N, Kaneda H, Toma T, Ohta K, Kasahara Y, and Koizumi S (1999) Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J Clin Investig 103: 129-135.[Medline]
Yamamoto M, Hayashi N, and Kikuchi G (1982) Evidence for the transcriptional inhibition by heme of the synthesis of delta-aminolevulinate synthase in rat liver. Biochem Biophys Res Commun 105: 985-990.[CrossRef][Medline]
Yang L, Quan S, and Abraham NG (1999) Retrovirus-mediated HO gene transfer into endothelial cells protects against oxidant-induced injury. Am J Physiol 277: L127-L133.
Yoshida T and Kikuchi G (1974) Sequence of the reaction of heme catabolism catalyzed by the microsomal heme oxygenase system. FEBS Lett 48: 256-261.[CrossRef][Medline]
Yoshida T, Oguro T, Numazawa S, and Kuroiwa Y (1987) Effects of phorone (diisopropylidene acetone), a glutathione (GSH) depletor, on hepatic enzymes involved in drug and heme metabolism in rats: evidence that phorone is a potent inducer of heme oxygenase. Biochem Biophys Res Commun 145: 502-508.[CrossRef][Medline]
Zager RA (1996) Mitochondrial free radical production induces lipid peroxidation during myohemoglobinuria. Kidney Int 49: 741-751.[Medline]
Zhang L and Guarente L (1995) Heme binds to a short sequence that serves a regulatory function in diverse proteins. EMBO (Eur Mol Biol Organ) J 14: 313-320.[Medline]
Zhang L and Hach A (1999) Molecular mechanism of heme signaling in yeast: the transcriptional activator Hap1 serves as the key mediator. Cell Mol Life Sci 56: 415-426.[CrossRef][Medline]
Zhu Y, Hon T, and Zhang L (1999) Heme initiates changes in the expression of a wide array of genes during the early erythroid differentiation stage. Biochem Biophys Res Commun 258: 87-93.[CrossRef][Medline]
This article has been cited by other articles:
|
|
 |
|
  P. Yao, L. Hao, N. Nussler, A. Lehmann, F. Song, J. Zhao, P. Neuhaus, L. Liu, and A. Nussler The protective role of HO-1 and its generated products (CO, bilirubin, and Fe) in ethanol-induced human hepatocyte damage Am J Physiol Gastrointest Liver Physiol, June 1, 2009; 296(6): G1318 - G1323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lanaro, C. F. Franco-Penteado, D. M. Albuqueque, S. T. O. Saad, N. Conran, and F. F. Costa Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy J. Leukoc. Biol., February 1, 2009; 85(2): 235 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Azadbakht and A. Esmaillzadeh Red Meat Intake Is Associated with Metabolic Syndrome and the Plasma C-Reactive Protein Concentration in Women J. Nutr., February 1, 2009; 139(2): 335 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Piantadosi, M. S. Carraway, A. Babiker, and H. B. Suliman Heme Oxygenase-1 Regulates Cardiac Mitochondrial Biogenesis via Nrf2-Mediated Transcriptional Control of Nuclear Respiratory Factor-1 Circ. Res., November 21, 2008; 103(11): 1232 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Patil, L. Bellner, G. Cullaro, K. H. Gotlinger, M. W. Dunn, and M. L. Schwartzman Heme Oxygenase-1 Induction Attenuates Corneal Inflammation and Accelerates Wound Healing after Epithelial Injury Invest. Ophthalmol. Vis. Sci., August 1, 2008; 49(8): 3379 - 3386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Markovitch, R. M. Tyrrell, and D. Thompson Acute moderate-intensity exercise in middle-aged men has neither an anti- nor proinflammatory effect J Appl Physiol, July 1, 2008; 105(1): 260 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Defrere, J.C. Lousse, R. Gonzalez-Ramos, S. Colette, J. Donnez, and A. Van Langendonckt Potential involvement of iron in the pathogenesis of peritoneal endometriosis Mol. Hum. Reprod., July 1, 2008; 14(7): 377 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Vinchi, S. Gastaldi, L. Silengo, F. Altruda, and E. Tolosano Hemopexin Prevents Endothelial Damage and Liver Congestion in a Mouse Model of Heme Overload Am. J. Pathol., July 1, 2008; 173(1): 289 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Nechemia-Arbely, D. Barkan, G. Pizov, A. Shriki, S. Rose-John, E. Galun, and J. H. Axelrod IL-6/IL-6R Axis Plays a Critical Role in Acute Kidney Injury J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1106 - 1115. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Dassen, R. Kamps, C. Punyadeera, F. Dijcks, A. de Goeij, A. Ederveen, G. Dunselman, and P. Groothuis Haemoglobin expression in human endometrium Hum. Reprod., March 1, 2008; 23(3): 635 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Lerner-Marmarosh, T. Miralem, P. E. M. Gibbs, and M. D. Maines Regulation of TNF-{alpha}-activated PKC-{zeta} signaling by the human biliverdin reductase: identification of activating and inhibitory domains of the reductase FASEB J, December 1, 2007; 21(14): 3949 - 3962. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Dimitrov, L. T. Roumenina, V. R. Doltchinkova, N. M. Mihaylova, S. Lacroix-Desmazes, S. V. Kaveri, and T. L. Vassilev Antibodies Use Heme as a Cofactor to Extend Their Pathogen Elimination Activity and to Acquire New Effector Functions J. Biol. Chem., September 14, 2007; 282(37): 26696 - 26706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. N. Porto, L. S. Alves, P. L. Fernandez, T. P. Dutra, R. T. Figueiredo, A. V. Graca-Souza, and M. T. Bozza Heme Induces Neutrophil Migration and Reactive Oxygen Species Generation through Signaling Pathways Characteristic of Chemotactic Receptors J. Biol. Chem., August 17, 2007; 282(33): 24430 - 24436. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Figueiredo, P. L. Fernandez, D. S. Mourao-Sa, B. N. Porto, F. F. Dutra, L. S. Alves, M. F. Oliveira, P. L. Oliveira, A. V. Graca-Souza, and M. T. Bozza Characterization of Heme as Activator of Toll-like Receptor 4 J. Biol. Chem., July 13, 2007; 282(28): 20221 - 20229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Liu, J. A. Simpson, K. R. Brunt, C. A. Ward, S. R. R. Hall, R. T. Kinobe, V. Barrette, M. Y. Tse, S. C. Pang, A. S. Pachori, et al. Preemptive heme oxygenase-1 gene delivery reveals reduced mortality and preservation of left ventricular function 1 yr after acute myocardial infarction Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H48 - H59. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Hodgson, N. C. Ward, V. Burke, L. J. Beilin, and I. B. Puddey Increased Lean Red Meat Intake Does Not Elevate Markers of Oxidative Stress and Inflammation in Humans J. Nutr., February 1, 2007; 137(2): 363 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Tracz, J. Alam, and K. A. Nath Physiology and Pathophysiology of Heme: Implications for Kidney Disease J. Am. Soc. Nephrol., February 1, 2007; 18(2): 414 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. B. Suliman, M. S. Carraway, L. G. Tatro, and C. A. Piantadosi A new activating role for CO in cardiac mitochondrial biogenesis J. Cell Sci., January 15, 2007; 120(2): 299 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Seta, L. Bellner, R. Rezzani, R. F. Regan, M. W. Dunn, N. G. Abraham, K. Gronert, and M. Laniado-Schwartzman Heme Oxygenase-2 Is a Critical Determinant for Execution of an Acute Inflammatory and Reparative Response Am. J. Pathol., November 1, 2006; 169(5): 1612 - 1623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Schaer, G. Schoedon, A. Imhof, M. O. Kurrer, and D. J. Schaer Constitutive Endocytosis of CD163 Mediates Hemoglobin-Heme Uptake and Determines the Noninflammatory and Protective Transcriptional Response of Macrophages to Hemoglobin Circ. Res., October 27, 2006; 99(9): 943 - 950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Brunt, K. K. Fenrich, G. Kiani, M. Yat Tse, S. C. Pang, C. A. Ward, and L. G. Melo Protection of Human Vascular Smooth Muscle Cells From H2O2-Induced Apoptosis Through Functional Codependence Between HO-1 and AKT Arterioscler. Thromb. Vasc. Biol., September 1, 2006; 26(9): 2027 - 2034. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Silva, A. Cunha, I. P. Gregoire, M. P. Seldon, and M. P. Soares The Antiapoptotic Effect of Heme Oxygenase-1 in Endothelial Cells Involves the Degradation of p38{alpha} MAPK Isoform J. Immunol., August 1, 2006; 177(3): 1894 - 1903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Furst, S. B. Blumenthal, A. K. Kiemer, S. Zahler, and A. M. Vollmar Nuclear Factor-{kappa}B-Independent Anti-Inflammatory Action of Salicylate in Human Endothelial Cells: Induction of Heme Oxygenase-1 by the c-Jun N-Terminal Kinase/Activator Protein-1 Pathway J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 389 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Schroder No Nitric Oxide for HO-1 from Sodium Nitroprusside Mol. Pharmacol., May 1, 2006; 69(5): 1507 - 1509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Overhaus, B. A. Moore, J. E. Barbato, F. F. Behrendt, J. G. Doering, and A. J. Bauer Biliverdin protects against polymicrobial sepsis by modulating inflammatory mediators Am J Physiol Gastrointest Liver Physiol, April 1, 2006; 290(4): G695 - G703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Abuarqoub, R. Foresti, C. J. Green, and R. Motterlini Heme oxygenase-1 mediates the anti-inflammatory actions of 2'-hydroxychalcone in RAW 264.7 murine macrophages Am J Physiol Cell Physiol, April 1, 2006; 290(4): C1092 - C1099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Liu, A. S. Pachori, C. A. Ward, J. P. Davis, M. Gnecchi, D. Kong, L. Zhang, J. Murduck, S.-F. Yet, M. A. Perrella, et al. Heme oxygenase-1 (HO-1) inhibits postmyocardial infarct remodeling and restores ventricular function FASEB J, February 1, 2006; 20(2): 207 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Wu and R. Wang Carbon Monoxide: Endogenous Production, Physiological Functions, and Pharmacological Applications Pharmacol. Rev., December 1, 2005; 57(4): 585 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Ogborne, S. A. Rushworth, and M. A. O'Connell {alpha}-Lipoic Acid-Induced Heme Oxygenase-1 Expression Is Mediated by Nuclear Factor Erythroid 2-Related Factor 2 and p38 Mitogen-Activated Protein Kinase in Human Monocytic Cells Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2100 - 2105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Schroder New signaling routes for an old drug: lipoxin A4 might mediate heme oxygenase-1 induction by aspirin. Focus on "Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells" Am J Physiol Cell Physiol, September 1, 2005; 289(3): C507 - C508. [Full Text] [PDF]
|
|
|
|
|
|
V. Nascimento-Silva, M. A. Arruda, C. Barja-Fidalgo, C. G. Villela, and I. M. Fierro Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells Am J Physiol Cell Physiol, September 1, 2005; 289(3): C557 - C563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Wijayanti, T. Kietzmann, and S. Immenschuh Heme Oxygenase-1 Gene Activation by the NAD(P)H Oxidase Inhibitor 4-(2-Aminoethyl) Benzenesulfonyl Fluoride via a Protein Kinase B, p38-dependent Signaling Pathway in Monocytes J. Biol. Chem., June 10, 2005; 280(23): 21820 - 21829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. W. Lam, S. J. Getting, and M. Perretti In Vitro and In Vivo Induction of Heme Oxygenase 1 in Mouse Macrophages following Melanocortin Receptor Activation J. Immunol., February 15, 2005; 174(4): 2297 - 2304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Arruda, A. G. Rossi, M. S. de Freitas, C. Barja-Fidalgo, and A. V. Graca-Souza Heme Inhibits Human Neutrophil Apoptosis: Involvement of Phosphoinositide 3-Kinase, MAPK, and NF-{kappa}B J. Immunol., August 1, 2004; 173(3): 2023 - 2030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. P. Carter, C. Garat, and M. Imamura Continual emerging roles of HO-1: protection against airway inflammation Am J Physiol Lung Cell Mol Physiol, July 1, 2004; 287(1): L24 - L25. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
 |
 |
 |
|
 |
 |
 |
-aminolevulinate synthase (ALA-S) (1); 
